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The Relationship Between B-type Natriuretic Peptide (BNP) Levels and Hospital 
  Length of Stay and Quality of Life in Congestive Heart Failure Patients 
 
 
Irma B. Ancheta 
 
 
ABSTRACT 
 Previous research on quality of life (QOL) and its relation to BNP levels in heart 
failure (HF) has been widely studied. However, the impact of physicians’ knowledge 
of BNP levels at time of clinic visit on QOL and hospital length of stay (LOS) has yet 
to be fully investigated. The purpose of this study were to determine if physicians’ 
knowledge of BNP levels affected a change in QOL scores at 90 days and reduce 
hospital length of stay among heart failure patients. QOL data from HF clinic patients 
(N= 108, 67.5 ±12.3, 56% male, ejection fraction 26.5 ± 8.2) were analyzed. QOL 
was measured at time of clinic visit (T1) and at 90 days (T2) using the Minnesota 
Living with Heart Failure Questionnaire (MLHFQ). An independent t-test was utilized 
to compare the two groups. Findings: Both groups were comparable regarding 
demographic and baseline characteristics. There was no significant association 
observed between the experimental and control group at 90 days, although the data 
indicated a decrease in the mean QOL scores at 90 days (37.46 ± 28.67) as 
compared to the mean QOL scores at baseline (46.87 ± 29.63) for both groups. 
 ix
Because the QOL scale is reversed, this indicated that there was a positive change in 
QOL scores during the 90 day time interval. Hospital LOS was similar for both groups 
(mean=3 days). BNP levels were significantly correlated with both baseline QOL 
scores (r=.25, p=.01) and physical subscale scores (r=.24, p=.01). Mortality was 
higher in the control when compared to the experimental group (t=1.99, df=90, 
p=.04). Conclusion: While physicians’ awareness of BNP levels had not shown a 
significant change in QOL at 90 days, patients’ QOL might already have been quite 
positive. Chronic HF patients may have adapted to their disease and have adjusted 
their perception of their QOL. Therefore, QOL may be a stable construct at this time. 
Findings may have been different on newly diagnosed HF patients since they may 
not have adapted to their health condition.  
 
 1
Chapter 1 
Introduction 
This chapter begins by defining congestive heart failure (CHF), discussing 
the etiology and pathophysiology of heart failure (HF), including the signs and 
symptoms, stages, and classifications to facilitate understanding of the disease 
process. This is followed by the presentation of the epidemiology of HF including 
the prevalence, incidence, risk factors, co-morbid conditions, mortality rates, and 
economic impact on the healthcare delivery system in the United States.  The 
effect of CHF on hospitalization, effect of CHF on quality of life (QOL) and the 
role of b-type natriuretic peptide (BNP) in HF will be explained. The statement of 
the problem, purpose of the study, research hypotheses, and definition of terms 
will be described. The definition of BNP and BNP-related studies will be 
discussed.  Finally, the underlying assumptions, delimitations, limitations, and 
significance of the study will be presented.  
Definitions of Congestive Heart Failure  
The Heart Failure Society of America (HFSA) 2006 Comprehensive Heart Failure 
Practice Guidelines (Adams et al., 2006) defines congestive heart failure as:                               
 A syndrome caused by cardiac dysfunction, generally resulting from 
 myocardial muscle dysfunction or loss and characterized by left ventricular 
 dilation or hypertrophy. Whether the dysfunction is primarily systolic or 
 diastolic or mixed, it leads to neurohormonal and circulatory abnormalities, 
 usually resulting in characteristic symptoms such as fluid retention, 
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 shortness of breath, and fatigue, especially on exertion. In the absence of 
 appropriate therapeutic intervention, HF is usually progressive at the 
 levels of cardiac function and clinical symptoms. The severity of clinical 
 symptoms may vary substantially during the course of the disease process 
 and may not  correlate with changes in underlying cardiac function. 
 Although HF is progressive and often fatal, patients can be stabilized, and 
 myocardial dysfunction and remodeling may improve, either    
 spontaneously or as a consequence of therapy.  In physiologic terms, HF 
 is a syndrome characterized by elevated cardiac filling pressure and/or 
 inadequate peripheral oxygen delivery, at rest or during stress, caused by 
 cardiac dysfunction. (p. 14)                                                                                           
The American College of Cardiology/American Heart Association (ACC/AHA) 
(2005) provides a scientific statement defining heart failure as                                                
 A complex clinical syndrome that can result from any structural or 
 functional cardiac disorder that impairs the ability of the ventricle to fill with 
 or eject blood. The cardinal manifestations of HF are dyspnea and fatigue, 
 which may limit exercise tolerance, and fluid retention, which may lead to 
 pulmonary congestion and peripheral edema. (p. e160)                       
Etiology                                                                                                                                     
 According to the ACC/AHA guidelines (2005), the underlying causes of HF 
in a substantial portion of patients are coronary artery disease, hypertension, and 
dilated cardiomyopathy. One-third of HF patients have nonischemic 
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cardiomyopathy, which may be caused by hypertension, thyroid disease, valvular 
disease, alcohol use, or myocarditis (ACC/AHA, 2005).                                                                
Pathophysiology of Heart Failure                                                                                               
 In HF, there is decreased cardiac output and increased pulmonary 
pressures consequently leading to pulmonary congestion. Because of this 
process, the body activates both neurohormonal pathways in order to 
compensate for low cardiac output. There is increased heart rate and contractility 
as initiated by the sympathetic nervous system. Catecholamines such as 
epinephrine and noepinephrine are circulated to cause artrial vasoconstriction 
and stimulate secretion of rennin from the kidney (ACC/AHA, 2005). These 
circulating catecholamines may exacerbate ischemia, cause arrhythmias or 
promote cardiac remodeling. Increased production or stimulation of the renin-
angiotensin system (RAAS) results in arterial vasoconstriction, sodium and water 
retention, and release of aldosterone, leading to sodium and water retention 
(ACC/AHA, 2005).                    
 On the other hand, nitric oxide and natriuretic peptides are hormones 
released by secretory granules in cardiac myocytes. Both are produced to 
counteract the effects of the vasoconstriction caused by catecholamine and 
rennin-angiotensin production. Nitric oxide and natriuretic peptides, to include b-
type natriuretic peptide (BNP), promote systemic and pulmonary vasodilation and 
increase sodium and water excretion. Continuous neurohormonal stimulation 
causes the left ventricle to undergo remodeling consisting of left ventricular 
dilatation, myocyte hypertrophy, and elongation. Enhanced neurohormonal 
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stimulation can lead to apoptosis, aggravation of ventricular contractility, and 
death (ACC/AHA, 2005). Chronic HF refers to the clinical syndrome 
characterized by signs and symptoms of increased tissue/organ water and 
decreased tissue/organ perfusion (Zile, 2005). HF is a common outcome for 
many cardiovascular diseases that results in symptomatic or asymptomatic left 
ventricular dysfunction (LVD). HF is a vicious cycle if left untreated. Dysfunction 
begets additional dysfunction that culminates in the demise of the patient 
(Ramakrishnan, et al., 2005).                                                                                                         
Signs and symptoms of heart failure                                                                                         
 The ACC/AHA guidelines refer to the cardinal manifestations of heart 
failure that include dyspnea, fatigue, which may limit exercise tolerance, fluid 
retention, which may lead to pulmonary congestion and peripheral edema (Hunt 
et al., 2005).  Signs and symptoms of congestive heart failure depend upon the 
side of the heart affected. Fatigue, orthopnea, wheezing or hacking cough, and 
shortness of breath during mild exertion are symptoms of left-sided failure.                                 
 Pulmonary edema occurs when too much fluid accumulates in the lungs. 
Since right-sided congestive heart failure reduces the amount of blood returning 
to the heart, the main symptoms are swelling in the feet, ankles, legs, and 
abdomen because the tissues throughout the body fill up with excess fluid. 
Patients with systolic heart failure experience feeling tired more often and have 
decreased appetite and increased weight gain (HFSA, 2006).                                                      
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Stages of Heart Failure                                                                                                                
 The staging of HF was devised to establish the evolution and progression 
of this disease. This HF classification was intended to complement but not 
replace the NYHA functional classification (ACC/AHA, 2005; HFSA, 2002).  
These levels or stages can only advance; the patient always goes forward not 
backward. This classification focuses on patients with HF as well as those who 
are at risk of developing HF (ACC/AHA, 2005). The following are the stages of 
HF as presented by the ACC/AHA guidelines: Stage A refers to the patient who 
is at high risk for developing HF but has no structural disorder of the heart (such 
as, hypertension or coronary artery disease); Stage B refers to an asymptomatic 
patient with a structural disorder of the heart (such as, LVD either dilation or 
hypertrophy); Stage C refers to the patient having underlying structural heart 
disease with past or current symptoms of HF; and Stage D refers to the patient 
with end-stage disease who requires specialized treatment strategies (Hunt, et 
al., 2001; Ramakrishnan, et al., 2005). Table 1 illustrates the stages of HF.                                 
 
 
 
 
 
 
Table 1:  
Stages of heart failure  
                                                                                                                                
American College of Cardiology/American Heart Association  
Classification of Chronic Heart Failure 
Stage Description 
A 
High risk for 
developing heart 
failure 
 
 
Hypertension, diabetes mellitus, CAD, family history of 
cardiomyopathy 
B 
Asymptomatic 
heart failure 
 
 
Previous MI, LV dysfunction, valvular heart disease 
C 
Symptomatic heart 
failure 
 
Structural heart disease, dyspnea and fatigue, impaired 
exercise tolerance 
D 
Refractory end-
stage heart failure 
 
Marked symptoms at rest despite maximal medical therapy 
 
Classification of Heart Failure                                                                                                     
 The New York Heart Association Classification (NYHA) criteria are utilized 
to assess the functional capacity of HF patients. The staging of heart failure has 
not replaced but complemented the functional classification of HF as categorized 
by the NYHA (ACC/AHA, 2005). Listed below is the NYHA classification 
according to the HFSA (2006). Class 1 refers to no limitation of physical activity. 
Ordinary physical activity does not cause undue fatigue, palpitation, and 
dyspnea. Class 2 refers to the presence of slight limitation of physical activity. 
Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, 
and dyspnea. Class 3 refers to the marked limitation of physical activity: 
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comfortable at rest but less than ordinary physical activity causes fatigue, 
palpitations, and dyspnea. Class 4 refers to the inability to carry out physical 
activity without discomfort, and symptoms of cardiac insufficiency at rest. If any 
physical activity is undertaken, discomfort is increased (HFSA, 2006). 
Epidemiology                                                                                                                           
Prevalence                                                                                                                                     
 As an epidemic disease and a major cause of chronic disability, CHF 
adversely affects the health of millions.  Nearly 5 million Americans are living with 
HF (ACC/AHA, 2005). CHF is the primary reason for 12 to 15 million office visits 
and 6.5 million hospital days each year.  Prevalence of HF in 2002 indicated that 
there were 4,900,000 of the total population with HF. The total number of males 
with HF was 2,400,000 (2.6%) and total number of females was 2,500,000 
(2.1%) (AHA, 2005). CHF increases with age: 7% of people 65-74 years of age 
and 10% of people over 75 are affected by HF (CDC, 2005).                                                        
Incidence                                                                                                                                      
 The incidence of HF showed 550,000 new cases annually or 10 per 1000 
after age 65. An estimated 80% of patients hospitalized with HF are more than 
65 years old (AHA, 2005). HF is a common Medicare diagnosis-related group 
with more Medicare dollars spent for the diagnosis, treatment, and management 
when compared to other diagnoses (ACC/AHA, 2005). Seventy-five percent 
(75%) of HF cases had a preexisting condition for hypertension. It is estimated 
that 22% of male and 46% of female patients who experience a myocardial 
infarction (MI) will most likely be diagnosed with HF within 6 years. According to 
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the National Heart Failure Data from the Acute Decompensated Heart Failure 
National Registry (ADHERE), the mean age of hospitalized HF patients was 71.2 
years old, and 52% of them were female (AHA, 2005).  Persons diagnosed with 
high blood pressure greater than 160/90 mm Hg have a twofold risk of having HF 
as compared to those with blood pressure less than 140/90 mm Hg (AHA, 2005). 
The annual rates of new HF cases per 1000 of non-black men ages 65-74 are 
21.5; ages 75-84 are 43.3; ages 85 and above are 73.1. The annual cases for 
non-black women ages 65-74 are 11.2; ages 75-84 are 26.3; and ages over 85 
are 6.9.  The annual rates of new HF cases for black men ages 65-74 are 21.1; 
ages 74-84 are 52; and over age 85 are 66.7. The prevalence for HF in black 
women is at 18.9, 33.5 and 48.4, respectively (AHA, 2005).                                                         
Risk Factors                                                                                                                                  
 The presence of multiple risk factors makes HF a more complicated 
diagnosis to manage and predisposes patients to frequent hospital admissions. 
Risk factors include smoking, diabetes, high blood pressure, high cholesterol 
levels, low high density lipoprotein (HDL) levels, obesity, and sedentary lifestyle 
(HFSA, 2006). Coronary artery disease, myocardial infarction (MI), hypertension, 
abnormal or damaged heart valves, damage to the heart muscle caused by 
alcohol or drug use, overexposure to radiation or viruses, heart defects from 
birth, severe lung disease, diabetes, severe anemia, overactive thyroid gland or 
cardiac dysrthymias are all considered causes of heart failure (AHA, 2005).  
Some reasons for HF are unknown. The most common risk factor for HF is 
hypertension. Uncontrolled hypertension increases the risk of heart failure by 
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200%, and people diagnosed with diabetes have a two- to eight-fold greater risk 
for developing HF (AHA, 2005).  
Mortality                                                                                                                                        
 An estimated 53,0000 patients have died of HF as a primary cause, and 
the mortality of HF has increased despite advances in treatment. in part due to 
better treatment and saving patients with MI earlier in life (ACC/AHA, 2005). It is 
estimated that 1 in 5 HF patients will die within one year of diagnosis (AHA, 
2005). Worst of all, HF patients suffer sudden cardiac death six to nine times 
more frequently than the general population (AHA, 2005). According to the 
AHRERE data, in-hospital mortality was 3.8% (AHA, 2005).                                                         
From 1992 to 2002, deaths from HF increased by 35.3%, and death rate 
increased to 7.7%. In 2000, there were 55,704 deaths occurring from HF; this 
mortality rate was a 148% increase from 1979 (National Center for Health 
Statistics, 2004).  The age-adjusted death rate was 20.2 (deaths per 100,000 
population) in 2000. Death rates were: for white males (21.0), black males (23.2), 
white females (19.4) and black females (21.3) (National Center for Health 
Statistics, 2004). The overall death rate for HF in 2001 was at 18.7 %, with 
19.6% for white males, 21.7% for black males, 18.1 % for white females and 
18.8% for black females (AHA, 2005).                                                                                           
Economic Impact                                                                                                                         
 In 1999, $3.6 billion was paid to Medicare beneficiaries diagnosed with HF 
(CMS, 2003). For 2005, an estimated direct and indirect cost of HF was $27.9 
million (AHA, 2005). The management of HF costs $56 billion a year, with 70% 
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due to hospitalization (Bhalla et al., 2004). Thus, HF has an enormous, 
escalating financial impact on healthcare expenditures (AHA, 2005; CDC, 2005).                        
  Effect of Congestive Heart Failure on Hospitalization                                        
 CHF is the most frequent cause for hospital readmissions, higher within 
the first 30 days after discharge than within 60 to 90 days (AHA, 2005). Hospital 
discharges increased by 152 percent from 377,000 in 1979 to 970,000 in 2002. 
According to the ADHERE registry, the mean hospital length of stay for HF 
patients was 5.8 days (median 4.3 days) (AHA, 2005).  
Several studies indicated that CHF is the primary diagnosis in most 
hospital admissions. In the Medicare study, chronic obstructive pulmonary 
disease, renal failure, and diabetes were medical conditions listed as other 
noncardiac comorbidities prevalent in older HF patients. Results of the Medicare 
study revealed that 40% of patients with HF had five or more noncardiac 
comorbidities; they accounted for 81% of the total inpatient hospital days. The 
presence of increased number of comorbidities in this patient population 
increased the risk of hospitalization (Braunstein et al., 2003). National databases 
on HF show that several studies have been conducted to reduce CHF 
hospitalizations. These studies include clinical trials on HF pharmacological 
management, HF device treatment, and non-pharmacological interventions to 
improve patient compliance and self-care behaviours (AHA, 2005).  
  Effect of Congestive Heart Failure on Quality of Life                                          
 The treatment of HF is complicated and frequently focused on 
improvement of quality of life (QOL) rather than on the recovery of the patient. 
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Patients with CHF often experience severe symptoms and deterioration of QOL 
(Moser, 2002; Rector, 2005; Luttik et al., 2005; Lee et al., 2005). To date, there 
remains confusion about the definition and measurement of QOL. For purposes 
of this study, QOL is defined as a multidimensional subjective description of the 
psychological, physical, and social domains of health as measured by the Living 
with Heart Failure Questionnaire (MLHFQ) (Rector, 2005).  
 The conceptual model by Rector et al. (2006) is used to guide this study. 
The model illustrates that the effects of HF on QOL are attributed to symptoms 
caused by HF. In the Valsartan Heart Failure Trial (VAL-HEFT) study, patients 
were asked to repeatedly assess several symptoms of HF and complete the 
MLHWF questionnaire. The purpose of the conceptual model was to assess 
patients’ perceptions of how heart failure affected their QOL. Other 
pathophysiologic measures were also used to assess the severity and secondary 
effects of HF. Results from both of these measurements were statistically 
analyzed to determine whether relationships exist among symptom assessments, 
pathologic measures, and MLHF scores. Using this secondary analysis of data 
from the VAL-HEFT study, the authors concluded that a significant proportion of 
the effects of HF on QOL is explained by the presence of symptoms of HF as 
measured by the MLWHF score and that the effects of QOL varies with age 
regardless of symptoms. Results of the study indicated that effects of HF on QOL 
with HF symptoms depend on HF pathology and that symptoms are the 
mediating factor on the effects on QOL (Rector et al., 2006).  
 
Figure 1 illustrates the model as described by Rector (2006).                                       
 
Figure 1: Conceptual model illustrating the effect of heart failure on QOL 
This conceptual model shows the effects of HF pathology on QOL, with HF 
symptoms as the mediating factor (Rector et al., 2006).  
 A domino effect is initiated from experiencing the physical symptoms 
leading to functional limitations suffered by HF patients. As HF advances and 
progresses, the disease prevents patients from living as they would have wanted. 
(Rector et al., 2006). Ordinary daily activities and recreational hobbies become 
difficult to perform without getting short of breath, lacking energy, or becoming 
easily fatigued. Patients with HF give up their independence since they must 
depend on others for menial tasks. This situation causes a variety of feelings 
such as frustration, hopelessness, depression, being a burden to the family,   
loss of self-control, and lowered self-esteem (Rector et al., 2006; Rector, 2005; 
Brostrom et al., 2004; Lee et al., 2005; Moser, 2002).                                                                   
 Literature reviewed on QOL indicates infrequency of treatment for 
psychological factors despite their role in the outcomes of heart failure, its 
association to QOL and to hospital admissions. It has been suggested that 
perception of life situation, psychosocial adjustment to illness, and functional 
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limitations are multi-dimensional areas that affect the QOL among heart failure 
patients. The perception of a life situation included how HF patients feel about 
their disease condition (Costelo & Boblin, 2004). Psychological adjustment to 
illness describes how depression, anxiety, social support, meaning, coping style, 
and spiritual beliefs affect QOL. The physical dimension includes functional 
limitations and HF symptomatology, self-care management strategies, and 
patient education in coping with a lifelong chronic condition.  Amelioration of 
physical symptoms may improve functional status, which may improve QOL. An 
increased awareness of HF patients’ life situations may lead to patients adapting 
to their CHF. Increased knowledge and ability to perform self-care may keep 
patients out of a vicious cycle of limitation and resignation. QOL, therefore, 
should be targeted as a relevant outcome measure when dealing with HF 
patients (Brostrom et al., 2004; Lee et al., 2005; Moser, 2002).                                                    
Role of B-Type Natriuretic Peptide (BNP) in Heart Failure 
CHF is a complex progression of domino effects involving cardiac and 
neurohormonal systems. BNP is a 32-amino acid hormone that was first found in 
the porcine brain. Subsequent studies found that b-type natriuretic peptide (BNP) 
level is a neurohormone produced by the left ventricle in response to fluid 
overload and released to the body’s systemic circulation (Masson et al. 2006; 
Brenden et al. 2006; HFSA,2006). 
 BNP is a biomarker of HF, and early detection of increased BNP levels 
may lead to early diagnosis and treatment of CHF, thereby decreasing 
readmissions and improving patients’ quality of life (QOL) (Heidenrich et al., 
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2004; Maisel et al., 2001; MacMahon et al., 2002). BNP is released in a pulsatile 
manner, approximately every 30 to 90 minutes in both healthy individuals and 
those with HF. However, in the presence of volume overload, there is a rapid 
elevation of BNP levels as evidenced by an increase in its pulsatile release 
(White, 2005). BNP inhibits sodium reabsorption in the distal tubules, increases 
globular filtration, and is involved in the regulation of diuresis. BNP antagonizes 
the vasoconstricting effects of the renin angiotensin-aldosterone system (RAAS), 
thereby regulating blood pressure and fluid balance (Chiong & Miller, 2002). BNP 
levels are elevated with cardiac overload and increased ventricular volume; they 
are sensitive to increased ventricular stretch (Mark & Felker, 2004). Ventricular 
volume expansion and fluid overload are evident in the early phases of CHF, 
thus becoming a marker for heart failure (Jiang et al., 2001; Maisel et al., 2002; 
Cheng et al., 2001; Ishii et al., 2003; Tabbizar et al., 2002; Anand et al., 2002).                           
 Activation of the neurohormonal system leads to progressive myocardial 
dysfunction and heart failure (Eichhorn & Bristow, 2001; Venugopal, 2001; 
Chiong & Miller, 2002). In the presence of volume overload, the cardiac 
ventricles stimulate BNP production and electrophysiologic arrthymias, 
suggesting the relationship between BNP and sudden death. Increased BNP 
levels are therefore a strong predictor of sudden death (Berger et al, 2002). 
Currently, BNP levels are not routinely tested during clinic visits (CMS, 2003), nor 
are they part of current CHF guidelines (HFSA, 2006; Howie, Caldwell & Dracup, 
2003).                                                                                                                 
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Studies of BNP in Heart Failure                                                                                                 
 The following research studies have shown how BNP levels are an 
indicator and a useful diagnostic tool for early stages of HF (Morrison et al. 2002, 
Ninuma et al., 1998; Wieczorek et al., 2002; Lubarsky & Mandell, 2004; Hirata et 
al., 2001; Teboul et al., 2004; Sagnella, 1998; Vanderheyden et al., 2004; 
Heidenreich et al., 2004; Mair et al., 1999). Taniguchi et al. (2006) conducted a 
study investigating the relationships between BNP and (QRS) duration to 
determine the prognostic value in HF patients. QRS duration and BNP levels 
were measured after patients (n = 93) were treated in the emergency 
department. Results showed that sudden death (6 patients,  348 ± 128 pg per ml) 
for progressive heart failure (9 patients, 390 ± 97 pg per ml), and readmission for 
worsening heart failure in (20 patients, 354 ± 79 pg per ml) occurred in 35 
patients. The authors concluded that high levels of BNP and prolonged QRS 
duration was associated with poor prognosis regardless of any type of cardiac 
events.  The study also suggested that a combination of both BNP levels and 
QRS duration may be useful in predicting the prognosis of HF patients.  
 Masson et al. (2006) investigated the prognostic value of BNP and amino 
terminal probrain natriuretic peptide (NT-proBNP) levels in stable, chronic HF 
patients. Baseline BNP and NT-proBNP levels were drawn from 3,916 patients 
enrolled in the Val-HEFT study. Findings reported that receiver-operator 
characteristic curves for all-cause mortality (area under the curve (SD) was BNP 
0.665 (0.011) vs. NT-proBNP 0.679 (0.011), p  =  0.0734). Sensitivity and 
specificity ranged from 0.590 to 0.696. The authors concluded that both BNP and 
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NT-proBNP showed slight differences in their relation to clinical characteristics 
and prognostic performance as a diagnostic tool in a large HF population and 
were the most powerful independent markers of outcome in HF. 
 Cardarelli and Lumicao (2003) conducted an extensive literature review on 
the prognostic and therapeutic monitoring value of BNP levels. They concluded 
that symptomatic patients without a history of CHF had BNP levels proportional 
to the severity and survival in CHF patients (BNP 80 pg per ml, sensitivities 93%-
98%, PV- 92%-98%). Those with BNP levels over 256.9 pg per ml deteriorated 
within the ensuing 12 months as compared to those with a BNP level of 42.4 - 
8.6 pg per ml who remained improved in their functional class. Another study by 
Berger et al. (2002) indicated that with cut-off point of BNP 130 pg per ml  
Kaplan-Meier survival rates were significantly higher in those patients with lower 
BNP levels than in those with values higher than the cut-off score (n = 452, p = 
.0001).                                                                                          
 Wieczorek et al. (2002) investigated the performance of the BNP rapid 
assay as a diagnostic tool in CHF, evaluating it in inpatient, outpatient, and 
healthy control subjects (n = 1050). Participants were classified into categories of 
those without CHF (n = 473), those with hypertension but no cardiovascular 
disease (n = 168), NYHA Class I (n = 73); Class II (n = 135); Class III (n = 141); 
and Class IV (n = 60). Using receiver operator characteristic (ROC) curves, 
results indicated that with a cut-off of 100 pg per ml, the assay showed a 
sensitivity of 82% and a specificity of 99%, validating the usefulness of BNP in 
the diagnosis of CHF and staging the severity of HF.                                                                   
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 The seven-site, international Breathing Not Properly Multinational Study 
(Maisel, 2002) examined if BNP was useful in predicting CHF patients with acute 
dyspnea in 1586 emergency department (ED) patients.  Two independent 
cardiologists were blinded to patients’ BNP measurements.  A receiver operator 
characteristic was used to illustrate various BNP levels. With a cut-off value of 
100 pg per ml, diagnostic accuracy of 83.4%, predictive negative value (PV-) of 
96% at 50 pg per ml, findings were: BNP alone was more accurate than any 
historical or laboratory values in predicting CHF as a cause of dyspnea. At least 
a non-systolic CHF patients showed significantly lower BNP levels than those 
with systolic heart failure (413 pg per ml vs. 821 pg per ml, p <0.001 for each 
pairwise comparison). The study concluded that, used in conjunction with other 
clinical assessment, BNP is useful in establishing or excluding the diagnosis of 
CHF.                                                                                                                        
 Morrison et al. (2002) enrolled 321 ED patients with dyspnea and 
determined if BNP levels could differentiate cardiac from pulmonary causes of 
dyspnea. Two physicians blinded to the BNP levels were asked to give their 
opinions on the probability of the patient having HF and their final diagnosis. The 
area under the ROC, which plots sensitivity and specificity of BNP levels 
differentiating cardiac from pulmonary, was .96 (p< 0.001). Results revealed that 
CHF patients (n = 137) had high BNP levels (758 to 798 pg per ml) as compared 
to those with pulmonary diseases (n = 85, 61 to 10 pg per ml).                                                     
 Hirata et al. (2001) examined the utility of BNP levels for early diagnosis of 
CHF and severity of the disease process in daily clinical practice.  For 415 heart-
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disease patients and 65 control-group subjects, comparison of BNP and atrial 
natriuretic peptide (ANP) levels using nonparametric Tukey type multiple 
comparison showed that BNP was higher than ANP (.864 vs. .787, p = 0.06). The 
area under the ROC curve (AUC) was used to evaluate the usefulness of both 
levels. With cut-off values of 15 pg per ml, BNP sensitivity was 74% and 
specificity of 83% in patients with cardiac disease. BNP levels correlate well with 
LVD, pulmonary artery wedge pressures, left ventricular hypertrophy, and 
systolic/diastolic dysfunction; levels higher than 100 pg per ml are highly 
suggestive of heart failure (ACC/AHA, 2001).                                          
 BNP levels not only accurately confirm the diagnosis of CHF but 
differentiate HF from other diseases (McCullough et al., 2003; Maisel et al., 
2002). A study conducted by Ninuma et al. (1998) examined if atrial natriuretic 
peptide (ANP) and BNP are effective methods of predicting heart disease 
irrespective of LVD.  Examining 481 patients, the study concluded that BNP was 
effective for screening asymptomatic patients with left ventricular dysfunction 
(BNP<13 pg per ml gave a predictive negative value of 100%).  The area under 
the receiver operating curve (ROC) for BNP was significantly greater when 
compared to ANP (0.94 vs. 081; p = .001).  Knowing the role the neurohormones 
play in the pathophysiology of HF makes for a better understanding and 
appreciation of BNP levels as a valuable test in the diagnosis of heart failure.            
                                       Statement of the Problem                                                                     
 Few studies have examined the relationship between clinicians’ 
knowledge of BNP levels and hospital length of stay (LOS) and quality of life in 
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heart failure (HF) patients. Troughton et al. (2000) concluded that current 
treatment strategies in the clinic ignore plasma neurohormone concentrations 
(BNP), even though they are independent markers of cardiac status and 
prognosis of heart disease including heart failure. Recent CHF guidelines do not 
target any hemodynamic criteria such as BNP levels prior to hospital discharge 
since most efforts have been focused on the use of pharmacological therapy and 
CHF management clinics (Troughton et al., 2000). Therefore, the goal of this 
study is to compare two CHF clinic groups: one with and one without clinicians’ 
knowledge of BNP levels and examine the relationship of physician knowledge to 
hospital LOS and QOL. 
Purpose of the Study 
The purpose of this study is [1] to determine if clinicians’ knowledge of 
BNP levels would make any difference in the QOL scores between the 
experimental and control groups at 90 days and [2] to determine if physicians’ 
knowledge or lack of knowledge of BNP levels at time of CHF clinic visit affect 
hospital LOS on all hospital admissions regardless of how many hospital 
admissions occur in 90 days. 
Research Hypotheses 
The effects of the study will be assessed by testing the following 
hypotheses: 
Hypothesis 1: It is hypothesized that clinicians’ knowledge or lack of knowledge 
of BNP levels at time of clinic visit makes a difference in the quality of life scores 
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between the experimental group and the control group at 90 days. An 
independent t-test between experimental and control groups was used to 
compare their mean QOL scores at 90 days.                                                
Hypothesis 2: It was hypothesized that clinicians’ knowledge or lack of 
knowledge of BNP levels at time of CHF clinic visit would affect hospital LOS on 
all hospital admissions of CHF patients within 90 days. A comparison of means 
for both experimental and control groups was used to examine the relationship 
between BNP levels and hospital LOS within 90 days.                                                                  
    Definition of Terms                                                                            
For the purpose of the study, the following terms are identified:                                                    
[1] Congestive heart failure: a complex clinical syndrome that can result from any 
structural or functional cardiac disorder that impairs the ability of the ventricle to 
fill with or eject blood (ACC/AHA, 2005). The cardinal manifestations of HF are 
dyspnea and fatigue, which may limit exercise tolerance, and fluid retention, 
which may lead to pulmonary congestion and peripheral edema (ACC/ AHA, 
2005). 
 [2] Systolic dysfunction: a defect in the ability of the cardiac muscles to shorten 
against a volume load. The ventricle loses its ability to eject blood into the aorta, 
and the LV systolic properties become abnormal (Zile et al., 2005).                                              
[3] Diastolic dysfunction: the inability of the cardiac muscle to rapidly or 
completely return to a resting state. At this point, the ventricle cannot accept 
blood at low pressures, and ventricular filling is slow or incomplete unless atrial 
pressure increases (Zile et al., 2005).                                                                                            
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[4] B-type natriuretic peptide (BNP): a cardiac neurohormone secreted from the 
cardiac ventricles as a response to ventricular volume expansion and fluid 
overload, evident in the early phases of congestive heart failure (Maisel, 2001; 
Mark & Felker, 2004).                                                                                                                    
[5] Hospital length of stay: number of days a patient stays in the hospital from 
time and date of admission to time and date of discharge.  Portions of a day were 
considered as one day of hospital stay.                                                                                         
[6] Quality of life: a multidimensional subjective description of the psychological, 
physical, and social domains of health as measured by the Living with Heart 
Failure Questionnaire (MLHFQ) (Rector, 2005). 
    Underlying Assumptions                                                                  
 The proposed study has some assumptions that are specific to the 
population of interest. The first assumption is that there is a correlation between 
BNP and HF. The second assumption is that early detection and knowledge of 
BNP levels may enable physicians to provide more aggressive treatment and 
titration of medications. The third assumption is that increased levels of BNP are 
directly related to poor QOL scores among heart failure patients. The fourth 
assumption is that timely detection and knowledge of BNP levels decreases 
hospital LOS.  
                                                   Delimitations                                                                             
 The sample included patients diagnosed with congestive heart failure.  
They had a wide range of ethnicity; were over 21 years of age; able to read, write 
and speak English; and had serum creatinine levels not greater than 2.5.                                    
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                    Limitations                                                                                   
 The limitations of the study included those that are generally experienced 
with quantitative study. First of all, the study population is focused on one clinic 
center, thereby limiting any generalization of findings to other geographical 
areas. Secondly, the participants of the study may have already been exposed to 
the same questionnaire in the past. Thirdly, there is a possibility of having 
measurement error in the study questionnaire. Lastly, there is a possibility of 
having random error in the BNP rapid assay machine. 
                                       Significance of the Study  
 Congestive heart failure is becoming one of the most chronic, debilitating, 
and progressive diseases in the United States. Numerous factors have been 
implicated in the disease, including coronary artery disease, hypertension, high 
cholesterol levels, diabetes, smoking, and diet and lifestyle behaviors. Despite a 
high level of public awareness of this disease, the majority of the population are 
unaware of their risks of having HF. By contributing to the body of knowledge 
concerning HF management, this study is intended to increase the understanding 
of the various factors that affect the success of managing HF patients. By 
measuring BNP levels, researchers will know how important the link is between 
BNP levels and QOL. By examining the relationship of B-type natriuretic peptide 
levels on CHF hospital LOS and QOL, this study may provide suggestions for 
future interventions that would allow patients to properly and timely treat the 
syndrome of HF. 
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 The research study may result in formulating and developing protocols 
that could provide heart failure patients with self-management strategies, 
allowing them more autonomy despite their health conditions, decreased hospital 
LOS, and enhanced QOL. The study furthers the science of nursing in that it 
seeks to investigate how clinicians’ knowledge of BNP levels affect hospital LOS 
and QOL among patients with HF. 
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Chapter 2 
Review of Literature 
  Chapter 2 describes an overview of congestive heart failure (CHF) as it 
relates to the study. The first area of the literature review describes quality of life 
(QOL) as experienced by heart failure patients. The second area of the literature 
review describes the effect of CHF on hospitalization. The third area discusses 
the role of b-type natriuretic peptide (BNP) in CHF hospitalization. Finally, 
physicians’ knowledge of BNP levels predicting heart failure (HF) treatment will 
be discussed.  
Introduction 
 Congestive heart failure (CHF) is the end stage of heart disease (AHA, 
2005).   It is a common diagnosis among elderly people who have multiple risk 
factors and co-existing illnesses and are on multiple medications. It is a chronic, 
disabling disease that causes patients to become dependent on others for their 
daily needs. Heart failure patients experience symptoms characterized by 
shortness of breath, edema, easy fatigability, and decreased physical endurance; 
these symptoms deter patients from activities that they enjoy. The prognosis is 
poor; patients experience deterioration of quality of life and frequent and regular 
hospital readmissions. The following is literature reviewed on QOL as 
experienced by patients living with heart failure, the effect of CHF on 
hospitalization, the role of BNP in CHF hospitalization, and physicians’ knowledge 
of BNP levels predicting treatment. 
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Quality of Life as Experienced by Heart Failure Patients 
  Quality of life (QOL) among HF patients is a subjective, multi-dimensional, 
concept that includes the physical, psychosocial, emotional, and spiritual aspects 
of life that change with time. It includes [a] the perception of life situation; [b] 
psychosocial adjustment to illness; [c] functional limitations of HF; [d] HF self-care 
management programs; and [e] patient education in HF (Brostrom et al., 2004; 
Sneed et al., 2001; Lee et al., 2005; Bosworth et al., 2004). Research correlating 
CHF and QOL indicate that the psychological factors are as important as the 
physiological factors (Moser, 2002; Riegel, 2006; Rector et al., 1993; Bennett et 
al., 1997; Clark et al., 2003; Konstam et al., 1996).   
[A] Perception of Life Situation 
  The empirical literature has found that several factors affect how QOL may 
be influenced by one’s perception of life situation: gender differences, HF 
patients’ and spouses’ perception of QOL, HF patients’ subjective perception of 
QOL, and objective evaluation of the severity of HF (Martensson et al., 2005; 
Costelo & Boblin, 2004; Luttik et al., 2005). 
Gender differences regarding perception of QOL in heart failure 
  Several studies show conflicting results regarding gender differences in 
the perception of QOL in HF. In a qualitative study conducted by Costelo and 
Boblin (2004), open, semi-structured interviews were used for clinic CHF patients 
(n = 6, 3 men and 3 women) with New York Heart Association (NYHA) Classes 
III–IV, with ages ranging from 37 to 87 years old.  The objective of the study was 
to identify whether gender differences influence QOL, treatment, and survival. 
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Data collection focused on the experience of the women and men with CHF; the 
two sources were those individuals with CHF and a family member for each 
participant. The study utilized a semi-structured one-on-one interview that lasted 
for one hour and occurred at the patients’ homes or in the CHF clinic. Open-
ended research questions were used to explore participants’ responses. Results 
revealed a total of 13 themes: burden to others, frustration, loss, acceptance, 
hope of the future, fatigue, maintaining independence, fear, physical symptoms, 
confusion due to lack of knowledge, isolation, depression, and shock and 
disbelief.  
  Three themes were identified from the subjects’ responses. First, the 
psychosocial impact of CHF is greater than the physical impact.  The author 
recommended that in addressing this issue, emphasis should be geared toward 
time for patients to verbalize their feelings and more time provided for the nurse 
to promote holistic assessment and to develop a therapeutic rapport with the 
patient. Second, men experienced more social isolation and loss, while women 
experienced fear. They recommended that healthcare providers should be aware 
of gender differences since men and women respond differently in coping with or 
accepting their illness.  Third, the depression experienced by patients with HF is 
influenced by age. The younger patients experience more physical limitations and 
depression when compared to older subjects. Nursing implications from this study 
included using depression scales as part of nursing assessment and thoroughly 
performing a comprehensive and holistic evaluation of the patients. 
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  On the other hand, Riegel et al. (2003) using secondary analysis from a 
previous study, examined 320 CHF men and women (N = 640) with matched 
functional status, age, ejection fraction, and marital status. Results showed 
minimal gender differences in QOL in patients with HF. Data from a convenience 
sample of nine experimental or quasi-experimental studies conducted in eight 
sites were used for the study. The MLWHF questionnaire was used to assess 
QOL between the treatment and control groups. The survey was administered at 
baseline and at 3 months. Results indicated that QOL was statistically significant 
and that QOL was minimally worse among women when compared to men (1-3 
points) at baseline and at 3 months. Emotional dimensions of QOL were lower in 
women than in men at baseline (p<0.03) but were small and statistically 
nonsignificant in 3 months. Therefore, the study concluded that gender 
differences in the perception of QOL are minimal in patients with HF. 
QOL as perceived among male heart failure patients 
  In 1997, Martensson et al. conducted a qualitative study describing how 
male patients with heart failure perceive their life situations. Once again, the 
phenomenographic approach was the method utilized for the study. Open semi-
structured questions were used for the interview. Twelve men diagnosed with 
CHF, with ages ranging from 48 to 80 years old, were enrolled in the study. 
Interview questions targeted the biophysical, socio-cultural, emotional, 
intellectual, and spiritual-existential dimensions. The data analysis compared 
different statements with similarities and differences. Six themes were identified: 
[1] a belief in the future that gave CHF patients a feeling of expectancy or being 
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self-influential; [2] gaining awareness was conceived of as being able to adapt to 
the symptoms and make the best of the situation; [3] feeling support from the 
environment; [4] feeling limitations was perceived as either social or physical 
limitation; [5]  feeling a lack of energy was described as mental and physical 
inabilities of setting about doing things that needed to be done; and [6] feeling 
resignation was conceived of as indifference, in which death was the only thing 
expected, or as powerlessness to influence their life situation. Recommendations 
from the study included patient education regarding CHF and its symptoms and 
focusing on self-care and other possibilities.  
QOL as perceived among women with heart failure  
  Martensson et al. (1998) conducted a study that showed how women with 
HF have a different perception of their life situation. The phenomenographic 
approach was utilized as the research design, describing something from a 
second person’s perspective (the patient’s experience of something or how 
something appears to someone). Methods used were open, semi-structured 
interviews based on the five dimensions of the holistic theory of Savrimaki and 
Stenbock-Hult (1993). The five dimensions were: biophysical, socio-cultural, 
emotional, intellectual, and spiritual-existential. Subjects were 12 CHF patients 
between 65 and 85 years old with various etiologies of heart failure. The study 
found that risk factors were different in women than in men.  
  Five categories or themes were identified: [1] feeling content with one’s 
past and present life; [2] a sense of support was conceived of as feeling 
abandoned or having a sense of devotion; [3] a sense of limitation was conceived 
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of as physical or social limitation; [4] feeling anxiety ranged from insecurity in 
relation to one’s self or in relation to one’s surrounding; and [5] powerlessness 
was perceived to be a feeling of worthlessness or being a burden. In this study, 
women were likely to experience guilt, anxiety, and decreased self-worth. 
Recommendations for future studies include nursing interventions that would 
focus on self-care abilities, setting realistic goals and expectations, providing a 
hopeful perspective, and empowering patients to have self-control and improved 
self-esteem.  
QOL as perceived by both heart failure patients and their partners 
  Ekman et al. (2002) described health related quality of life (HRQOL) and 
sense of coherence (SOC) in a group of elderly HF patients with moderate to 
severe heart failure in comparison to a healthy control group (n = 94). Methods 
used included matching HF patients to healthy control subjects. The SF-36 health 
survey was used to assess QOL health status, and the Antonovsky Sense of 
Coherence Scale (SOC) measured overall orientation toward demanding life 
situations. Significant differences were found between men and women. Male 
subjects diagnosed with HF scored higher in the physical dimension of the SF-36 
(33 vs. 45, p = 0.0005) vs. healthy controls (57 vs. 77, p = 0.036).  
  Findings revealed that old-age and severe heart failure were associated 
with lower levels of HRQOL scores as compared to healthy controls. The study 
claimed that a state of tension occurs when a stressor in life is present and that 
successful coping or management of stress can lead to better health. This means 
that the presence of an individual’s social, cultural, and historical contexts is 
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helpful in making stressors in life more manageable, comprehensible, and 
meaningful.   
  Luttik et al. (2005) conducted an explorative study of QOL as perceived by 
HF patients and QOL as perceived by their partners. The study enrolled 38 heart 
failure couples, 31 male and 7 female patients.  The Cantril Ladder of Life 
instrument was used to assess the QOL.  Results indicated that the mean QOL 
scores for QOL (present) for HF patients was 6.8 as compared to partners at 5.0 
(p<0.025). Mean QOL (past) scores for HF patients was 4.9 as compared to 
partners at 6.1 (p<0.03). In this study, HF patients experienced a poor QOL both 
in the past and in the present as compared to their partners. However, the QOL 
expectation scores 3 years in the future did not differ significantly (6.7 vs. 6.4, p = 
0.60).  
Subjective perception of QOL and objective evaluation of the severity of 
heart failure 
  Grigoni et al. (2003) studied the distance between patients’ subjective 
perception of QOL and objective evaluation of the severity of HF. The study 
investigated the relationship between QOL (what patients are most interested in) 
and objective parameters of CHF severity (largely physician care). QOL was 
evaluated using the MLWHF questionnaire; objective clinical indicators used were 
the electrocardiographic, echocardiographic, hemodynamic and functional 
capacity. Results revealed that sinus rhythm (p = 0.007), NYHA class (p<0.001), 
and the distance covered with the 6-minute walk test (p<0.001) were correlated 
with QOL.  Therefore, the study recommended the possibility of cost-effective 
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non-pharmaceutical therapeutic approach in improving QOL heart-failure 
management as a much needed approach in the management of heart failure.  
[B] Psychosocial Adjustment to Illness  
  The empirical review found that psychological factors such as depression, 
anxiety, and coping styles affect QOL in HF patients (Zambroski et al., 2005; 
Artinian et al., 2004; Carels, 2004; Martensson et al., 2003; Dracup et al., 1992). 
Depression in CHF has been well documented in several studies of heart failure 
(Johansson et al., 2006; Turvey et al., 2006;  Konstam et al., 2005; Costelo & 
Boblin, 2004). An estimated $5 billion of the total $20 billion cost associated with 
heart failure may be associated with depression. The prevalence of depression 
among hospitalized HF patients ranged from 15% to as high as 77.5%; 
outpatients with HF and depression ranged from 13% to 42% (Gottlieb et al., 
2004). The summary of the cross-sectional studies conducted by Havranek et al. 
(1999), Majani et al. (1999), and Koenig et al. (1998) indicated the presence of 
higher levels of depression in the heart failure population. The longitudinal study 
conducted by Murberg et al. (1999) revealed that depressed mood is a significant 
indicator of mortality at 2-year follow-up of CHF patients (MacMahon & Lip, 2002). 
Depression as experienced among heart failure patients 
  Evangelista et al. (2006) studied the relationship of depression and 
obesity on health related quality of life (HRQOL) in patients from a tertiary HF 
clinic (n = 358). The Beck Depression Inventory (BDI), MLWHF questionnaire, 
and body mass index were utilized in measuring the variables of the study. The 
authors reported BMI results in relation to overall MLWHF, physical subscale, and 
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emotional subscale scores were significant (p<0.001).  The study concluded that 
obese HF patients have significantly poorer HRQOL, physical health, and 
emotional well-being; they also have more depressed symptoms.  
  Lesman-Leegte et al. (2006) evaluated depressive symptoms among 
elderly hospitalized HF patients (n = 572). Depression was measured using the 
Center for Epidemiological Studies Depression Scale (CES-D). Findings reported 
that 41% had symptoms of depression, women more than men (48% vs. 36%,  
X2 = 8.1, p<0.005). Multivariable logistic regression showed that women had more 
depressive symptoms (OR.68, 95% CI 1.14-2.48), COPD (OR 2.11, 95% CI 1.35-
3.30), sleep disturbance (OR 3.45, 95% CI 2.03-5.85) and loss of appetite (odds 
2.61, 95% CI 1.58-4.33).  The authors concluded that depression was more 
prevalent in elderly women than in elderly men hospitalized with HF.    
  Martensson et al. (2003) conducted a study on CHF patients and spouses 
regarding different levels of depression and health related quality of life (HRQOL). 
The study used a two-group comparative design and enrolled 48 couples with all 
men diagnosed with heart failure. Depression was assessed using the Beck 
Depression Inventory (BDI), and HRQOL was assessed using the SF-12 health 
survey. Results revealed gender differences regarding the presence of 
depression.  Patients with HF had significant differences in depressive symptoms, 
with men having a mean of 10.5 ± 7.3, whereas their spouses had a mean of 7.0 
± 5.6 (p<0.006). The authors recommended strategies and interventions that 
would include enhancing education and communication between the couples 
(patients and spouses).  
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  Sullivan et al. (2002) conducted a study evaluating 1,098 health 
maintenance organization patients categorized into three groups. Group 1 
includes those with no depression (n = 672; cost of $7,474 per patient per year), 
group 2 includes those with antidepressant prescription only (n = 312; cost,  
$11 012 per patient per year), and group 3 includes those with antidepressant 
prescription and depression diagnosis recorded (n = 114; cost, $9550 per patient 
per year). Healthcare costs were 26% higher in group 2 (antidepressant 
prescription only), 29% higher in group 3 (antidepressant prescription and 
depression diagnosis) as compared to the no-depression group 1 (p<.001), 
suggesting that healthcare costs are significantly higher for patients with 
depression. 
  Moser et al. (2005) studied the prevalence of psychological, social, and 
behavioral risk factors in patients recently hospitalized with HF. The randomized 
study recruited participants from three community hospitals (n = 202). The 
modifiable risk factors measured were depression, QOL, assessment of 
symptoms, health, and medical compliance. The Multiple Adjective Affect 
Checklist was utilized to measure depression and anxiety. The MLWHF 
questionnaire was used to measure HRQOL. The dyspnea and fatigue index was 
used to measure symptom status. Health compliance was measured by analyzing 
the documentation of the intervention nurse. Using the Multiple Adjective Affect 
Checklist, a score > 7 represented presence of anxiety and a score of > 11 
indicated presence of depression. Results showed that the mean anxiety level 
was 7.8 ± 4.6 (median 7.0, range 0-21) and mean depression level was 15.6 ± 8.4 
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(median 16, range 1-37). Anxiety was present in half of the participants (50%), 
and 5% had double the anxiety levels from the cut-off point. The authors 
concluded that the presence of psychological, social, and behavioral risk factors 
are prevalent among discharged HF patients.  
[C] Functional Limitations 
  The lack of mental and physical energy may cause CHF patients to have 
functional limitations. These limitations may cause patients with heart failure to 
lose hope and feel a sense of resignation that neither they nor their environment 
can influence their medical predicament (Martensson, 1997). Symptoms of 
congestive heart failure include shortness of breath, fluid retention, which may 
lead to pulmonary congestion and peripheral edema, fatigue that limit exercise 
tolerance, and general body malaise that limit daily activities (Hunt et al., 2005). 
Symptom severity and symptom burden 
  Insomnia and sleep disordered breathing are the most severe and 
burdensome symptoms of HF associated with poor QOL (Zambroski et al., 2005; 
Konstam et al., 2005; Brostrom et al., 2004). Sleep disordered breathing (SDB) is 
a cardinal symptom of HF associated with poor QOL (Ferrier et al., 2005;  
Trupp et al., 2004; Brostrom et al., 2004). SDB is inclusive of both central sleep 
apnea (CSA) and obstructive sleep apnea (OSA). 
  Zambroski et al. (2005) conducted a study regarding symptom severity, 
prevalence, and burden on QOL among patients with heart failure (n = 58). The 
method used for the study was a cross-sectional descriptive design. Physical and 
emotional symptoms were assessed using the Memorial Symptom Assessment 
 35
Scale-Heart Failure. Functional status was assessed using the Dyspnea Fatigue 
Scale and NYHA classification. HRQOL was assessed by the MLWHF 
questionnaire.  
  Total mean scores reported for the MLWHF questionnaire were 60.1± 
21.5. Results indicated that there was a high symptom prevalence of shortness of 
breath (2.7 ± 1.0), lack of energy (2.9 ± 0.1), dry mouth (2.5 ± 1.1), feeling drowsy 
(2.4 ± 1.0), and difficulty sleeping (3.0 ± 1.0). The prevalence of psychological 
symptoms included difficulty of concentrating, worry, sadness, nervousness, and 
irritability. Difficulty sleeping was rated as the most frequent and severe symptom 
at 94% and 98%, respectively. When compared to chest pain, difficulty sleeping 
was the most burdensome symptom (2.1 ±1.1 vs. 2.8 ± 0.8, p<0.001). 
  Results included both the total prevalence score and the total burden 
score. The four variables explained 67% of the variance for the HRQOL model; 
age (b = −.30, p < .01), NYHA functional class (b = .22, p = .02), total burden  
(b  =  .32, p < .01), and finally, total prevalence (b = .32, p = .01). This meant that 
younger patients and those with higher NYHA classification had greater symptom 
burden and greater symptom prevalence and therefore predicted a worse QOL. 
The study concluded that patients with HF experience high levels of symptoms 
and symptom burden that affect their QOL. The authors recommended thorough 
assessment, identification, and treatment of sleep disorder symptoms as crucial 
steps in providing a better QOL. 
  Brostrom et al. (2004) conducted a study describing the relationship of 
self-assessed sleep difficulty, daytime sleepiness to HRQOL in HF, and 
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compared to the healthy population. A cross-sectional design was used for the 
study. Outcome measures were assessed using the Uppsala Sleep Inventory-
Chronic Heart Failure, Epworth Sleepiness Scale, SF-36 and the Minnesota 
Living With Heart Failure Questionnaire (MLWHFQ). For the study, 223 CHF 
patients with NYHA Classes II-IV were recruited. Results revealed that sleep was 
shorter for women (p<0.05) while men had an increased number of sleep 
awakenings (p<0.001). Patients who had a difficult time maintaining sleep, 
initiating sleep, and had early morning awakenings reported lower HRQOL as 
compared to the normal population (p<.05-p<.001). The most significant 
difference were in the areas of general health, vitality, and social functioning 
(p<0.001). The MLWHF questionnaire total was 37.4 ± 21.9 for men vs. 39.9 ± 
25.6 for women. The score on the physical subscale was 16.3 ± 10.3 for men as 
compared to 17.9 ± 9.8 for women, and on the emotional subscale 6.8 ± 6.3 for 
men as compared to 6.0 ± 5.4 for women. The number of frequent awakenings 
per night were significantly more in men (p<.001), and the ratio of habitual sleep 
to the amount of estimated need for sleep was significantly shorter in women 
(p<.05).  
  Sleep apnea can stimulate neurohormonal and hemodynamic changes in 
HF. Fifty percent (50%) of HF patients have sleep apnea and significantly worse 
outcomes when compared to those HF patients who do not have SDB. Daytime 
tiredness is the most prominent symptom of sleep apnea (Brostrom et al., 2004). 
HF patients suffering from SDB have poorer HRQOL, as seen in significant 
decrease in seven to eight domains measured by the SF-36 (n = 223, p <.05 to 
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p<.001) as compared to the normal population (Brostrom at al., 2004). Patients 
suffering from difficulties initiating sleep (DIS), difficulties maintaining sleep 
(DMS), early morning awakenings (EMA), and excessive daytime sleepiness 
(EDS) showed significantly decreased HRQOL as measured by MLWHF. Total 
MLWHF score in HF patients with DIS was 49.0 ± 24.1 (n = 42); 51.2 ± 22.9  
(n = 48) in HF patients with DMS; 54.9 ± 22.4 (n = 33) in HF patients with EDS; 
and 47 ± 21.7 (n = 47) with EDS.  HF patients suffering from DIS, DMS, EMA, 
and EDS had significantly decreased HRQOL, measured by MLWHF, compared 
to the whole group of patients with HF (p<.05 to p<.001).  
  Physical symptoms as indicators of heart failure are not obvious when 
compared to patients with diabetes (Kodiath, 2005). For example, diabetic 
patients can monitor their blood glucose levels, but when HF patients gain 3 to 5 
pounds, they are already ill. Empowering HF patients to become active 
participants rather than passive observers of their health situation is, therefore, 
critical and essential. 
[D] Self-Care Management 
  Disease state management is an evidenced-based program designed to 
provide prevention, screening, and monitoring of patients’ health and education, 
thereby increasing compliance and autonomy regarding patients’ control of their 
health (ACC, 2001; HFSA 2006). Disease state management follows ACC/AHA 
guidelines in the use of beta blockers, diuretics, digoxin, and angiotensin 
converting enzyme (ACE) inhibitors for patients with left ventricular systolic 
dysfunction with or without symptomatic heart failure, and the use of 
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spironolactone in patients with severe heart failure. It is a systematic, proactive 
case management model that utilizes an organized approach in providing early 
intervention and an active patient self-care participation for optimum health 
maintenance (ACC/ AHA, 2005; HFSA, 2006).   
  The empirical literature review indicated that non-pharmacologic 
interventions such as a supportive nursing intervention may be an effective tool in 
improving QOL in the HF patient population (Riegel, et al., 2006; Karlsson et al., 
2005; Harrison et al., 2002; Jaarsma et al., 2000). Home care nursing influences 
self-care and self-efficacy in the HF population by providing the following: a 
supportive familiar environment wherein patients can perform physical activities 
(performance mastery); encouragement and support (verbal persuasion); 
guidance and sharing of vicarious experiences; and a realistic approach and 
evaluation of individual abilities (physiologic state) (Borsody et al., 1999). 
  Riegel et al. (2006) conducted a mixed method, pretest posttest design 
evaluating the motivational intervention program to improve HF self-care. Both 
quantitative and qualitative data were used to analyze participants’ responses. 
Participants (n = 15) received a motivational intervention designed to help 
patients increase their intention to change behavior by changing attitude about 
change. An advanced practice nurse trained in motivational interviewing and 
counseling did an average of 1.5 to 3.0 home visits over a 3-month period to HF 
patients. Self-care was measured using the Self-Care of HF Index (SCHFI), 
designed specifically for HF patients. The authors reported that both qualitative 
and qualitative analysis showed participants improved their self-care behaviors 
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after receiving intervention by 71.4% (10 of 14). The study concluded that 
motivational intervention programs provided to HF patients improve HF self-care.  
  Karlsson et al. (2005) conducted a nurse-based outpatient clinic study that 
randomized HF patients to either the intervention group (followed up at a nurse-
based outpatient clinic; n = 103) or the control group (followed up at the primary 
healthcare clinic; n = 105). Patients’ cognitive functioning was assessed using the 
Mini Mental State Examination (MMSE) at baseline and at 6 months. Results 
revealed that men knew more about CHF at baseline as compared to women 
(p<0.01). However, women in the intervention group increased their knowledge 
regarding self-care between baseline and 6 months as compared to the women in 
the control group (p<0.05). The study concluded that women gained more than 
men from a nurse-based management program. Patients with cognitive 
dysfunction who had low scores on the MMSE (<24) presented lower scores on 
knowledge of CHF as compared to those with higher (>24) at baseline (p<0.001). 
Differences in scores disappeared after intervention was given.  The authors, 
therefore, recommended that patients with cognitive dysfunction should not be 
discouraged from participating in the program.  
  Harrison et al. (2002) conducted a prospective randomized study of a 
nurse-led intervention focused on the transition from hospital-to-home and 
supportive care for self-management 2 weeks after hospital discharge. The 
purpose of the study was to find out if providing a nurse-led intervention would 
promote a better QOL. The study enrolled patients (n = 75 per group) randomized 
to either the transitional care or the usual care. Three months after discharge, 
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31% of the usual care patients were readmitted as compared to 21% of the 
transitional care groups. Emergency department visits were higher in the usual 
care group at 46% as compared to the transitional care group at 29% (t = 4.86, df 
= 1, p<0.03). Results showed that at baseline, physical dimension mean scores 
for the usual care were 25.45 (SD = 9.77) and transitional care mean score was 
25.46 (SD = 9.55). At 6 weeks after hospital discharge, the total MLHFQ score 
was better among the transitional care patients (27.2 ± 19.1) than among the 
usual care patients (37.5 ± 20.3, p = 0.002). The MLWHF questionnaire total 
score in 12 weeks for the usual care had a mean score of 38.39 (SD = 18.24); the 
transitional care had a mean score of 25.76 (SD = 19.44) (p<0.001).  The study 
concluded that significant improvements in health-related quality of life (HRQL) 
were associated with transitional care and decreased visits to the emergency 
rooms were noted.  
  Jaarsma et al. (2000) conducted a study to test the effectiveness of a 
supportive nursing intervention regarding self-care abilities, self-care behavior, 
and QOL in CHF patients (n = 179). An experimental design with random 
assignment to two groups, an intervention group and a treatment control group. 
Outcome measures on self-care abilities utilized the Appraisal of Self-Care Scale. 
Three dimensions of QOL were measured. These included functional capabilities, 
symptoms, and psychosocial adjustment to illness. Functional capabilities were 
measured using the Heart Failure Functional Status Inventory. Symptoms were 
measured using a ten-point scale questionnaire. Psychosocial adjustment to 
illness was measured using the Psychosocial Adjustment to Illness Scale (PAIS). 
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Overall well-being was measured utilizing the Cantril's Ladder of Life Survey. 
Education took place at the hospital and at home. The home visit was scheduled 
a week after discharge. Data collected included self-care abilities, self-care 
behavior, hospital readmissions, visits to the emergency department, and use of 
other healthcare resources.  
  Findings indicated that the intervention group reported better compliance 
as compared to the control group at 3 months (12.2 vs. 10.6; t = 2.9, p = .005) but 
was not significant different at  9 months (11.2 vs. 10.3; t = 1.6, p = .11). 
Symptoms decreased significantly in both groups, from 3.9 at baseline to an 
average of 1.9 symptoms in the control group versus 2.2 symptoms in the 
intervention group at 3 months of follow-up (p <.001).). Total PAIS scores for both 
groups decreased significantly, indicating better psychosocial adjustment to 
illness (control: t = 2.3, p = .03; intervention: t = 2.3, p = .03). There was no 
difference demonstrated between the two groups at the three points in time. Heart 
failure self-care behavior correlated slightly with the overall score of well-being 
only at 9 months after discharge (r = 0.24, p <.05). The study concluded that 
education from a nurse provided at the hospital and at home significantly 
increased self-care behavior for both groups at one month but was significantly 
increased in the intervention group (control: 12.2 – 2.9 vs. 13.8-3.4, p<0.001).   
[E] Patient Education 
  Kuztleb and Reiner (2006) conducted a prospective quasi-experimental 
multi-center study on the impact of nurse-directed patient education on QOL and 
functional capacity in people with HF. Patients were grouped to either the nurse-
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directed care (NC) (n = 13) and the routine care (RC) (n = 10). The NC group 
received comprehensive disease state management education and weekly 
telephone follow-up while the RC received protocol-driven medical management. 
Both groups were followed up to 12 months. QOL was measured using the 
Ferrans and Powers (1992) Psychometric Tool.  This QOL instrument consists of 
two parts. The first part measures satisfaction with various aspects of life, and the 
second part measures the significance of those aspects. Scores were measured 
for overall QOL and in four domains: health and functioning, psychological and 
spiritual, social and economic, and family. Scores range from 0 to 30, and a 
significant correlation exists between higher QOL and higher scores. Findings 
showed that the domains of total QOL were significantly improved in the NC 
group (F = 13.569, p = 0.000), health and function (F = 3.995, p = 0.003), social 
and economic (F = 14.109, p = 0.000), psychological and spiritual (F = 13.212,  
p = 0.000) and family (F = 2.384, p = 0.048). The study concluded that a nurse-
directed patient education improved QOL and improved functional capabilities.  
  Gonzalez et al. (2005) conducted a prospective study to evaluate if a 
nurse-guided education changes self-care behavior in an outpatient HF 
population. The study utilized a questionnaire given to HF patients at time of visit 
and at one year; it evaluated how the nurse electronic-guided education changed 
self-care behavior in regard to knowledge of the disease and treatment, and 
weight and blood pressure monitoring (n = 298).  Results indicated that initially 
only 28% of patients understood the disease, but 55% understood the disease 
after one year of follow-up (p<0.001). Awareness of more than three symptoms 
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increased from 66.5% to 85.5% (p<0.001). Medication knowledge increased from 
33% to 44% (p<0.001). Weight monitoring compliance increased from 21% to 
39% (p<0.001), and weekly blood pressure monitoring increased from 28.5% to 
43% (p<0.001).  Results reported that only 30% understood HF and 56% 
understood the disease at one year (p<0.001, N = 298). Knowing signs and 
symptoms of HF increased from 66.5% to 86.5% (p<0.001).  Knowledge of 
medications increased from 33% to 44% (p<0.001). Initially, 63% monitored their 
weight only at clinic visit, and 21% monitored their weight at least once a week. 
After one year, these percentages were 16% and 39% respectively (p<0.001). 
Initially, only 45% were monitoring their blood pressure and 28% checked it once 
a week. At one year these percentages were 12% and 43% respectively 
(p<0.001).  
  Kodiath et al. (2005) conducted a one-group design study. The purpose of 
the study was to find out if behavioral self-management enhances health-related 
quality of life (HRQL). The behavioral intervention was implemented among a 
sample of HF patients (n = 58) to help participants establish healthy behaviors 
that would improve their quality of life. The intervention consisted of 2-hour group 
classes and telephone call follow-up over a period of 15 weeks. Patients were to 
change one of the following behaviors: diet, exercise, smoking, sodium, or alcohol 
consumption. The method incorporated the components of the Information 
Motivation Behavioral (IMB) Skills Model that included information, motivation, 
and behavioral skills. Feedback forms were given to all who attended at the end 
of all classes. Major themes were described such as depression, satisfaction with 
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the intervention, participants’ lack of understanding of HF, denial or disbelief 
concerning the diagnosis, the influence of age, confusion regarding access to 
care, lifestyle changes, and depression. The study concluded that in this patient 
population (CHF patients), choosing to change a health behavior was difficult 
because the physical indicators (such as weight gain) following the change were 
not obvious (Kodiath et al., 2005). 
Effect of CHF on Hospitalization 
  Heart failure is significantly related to increased hospitalization (AHA, 
2005).  In the data from 1980 to 2002, reported from the Center for Disease 
Control and Prevention (CDC) on heart failure as a first-listed diagnosis, the 
average length of stay (LOS) of hospital discharges decreased by 6.6 days (from 
11.9 to 5.3 days). The data reported a trend in the decreased average LOS 
among all ages, regardless of sex and race. Hospital discharges with heart failure 
as first diagnosis accounted for more than 1.8 million days of hospital stay, for an 
average LOS of 5.3 days (Center for Disease Control (CDC), 2005). The age-
specific rates of hospital discharges for heart failure patients when listed as first 
diagnosis for all age groups increased during the 1980s and mid 1990s. From 
1998 to 2002, age-specific rates leveled off in the 0-64 age group and declined in 
people aged 75 and older (CDC, 2005). Age-adjusted hospital discharge rates 
were similar for men and women throughout the time period of 1980-2002.    
Role of B-Type Natriuretic Peptide (BNP) in CHF Hospitalization 
  Managing CHF costs $56 billion a year, with 70% due to hospitalization 
(Bhalla et al., 2004).  Increased predischarge levels of BNP predicts hospital LOS 
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after decompensated CHF (Cheng et al., 2001; Mueller et al. 2004). Conversely, 
BNP levels provide a measurable guide for the estimation of timely diagnosis of 
heart failure (Prahash & Lynch, 2004; Maisel et al., 2001; Wieczorek et al., 2002; 
Troughton et. al., 2000).  Thus early intervention can alleviate symptoms and 
delay or halt disease progression; regular clinic visits and management can 
potentially decrease hospital LOS by 3 days (Mueller et al., 2004). 
Clinical studies indicating relationship between BNP levels and CHF 
hospitalization 
  Hogenhuis et al. (2006) conducted a study investigating the prevalence 
and characteristics of HF patients (n = 601) with BNP levels <100 pg per ml and 
categorized using NYHA Class II-IV. Patients were enrolled in the study following 
hospital discharge with diagnosed heart failure. Results showed that patients with 
BNP levels < 100 pg per ml had higher left ventricular ejection fraction compared 
with those with BNP levels > or = 100 pg per ml (0.41 ± 0.14 vs. 0.33 ± 0.13,  
p < .001). The authors concluded that clinically stable patients with a recent 
admission for decompensated HF, and with low BNP levels seemed to have less 
severe HF and preserved systolic function as compared to those patients who 
had BNP levels > or = 100 pg per ml. 
  Valle et al. (2005) conducted a study that measured BNP levels in 
ambulatory patients with HF with preserved left ventricular ejection fraction 
(LVEF), including how BNP levels can predict the occurrence of cardiovascular 
events in 6 months. BNP levels were drawn on HF outpatients (n = 233). 
Outcome measures included cardiovascular death (n = 15) or hospital 
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readmission (n = 33). Results revealed that BNP levels were a strong predictor for 
subsequent events (ROC, area under curve = 0.84; CLI = 0.78-0.88). BNP cut-off 
levels of 200 pg per ml found in 67% of patients (HR = 2.2, p< 0.4) predicted 9% 
event rate within 6 months. BNP levels of 500 pg per ml or more found in 10% of 
the patients (HR = 5.8, p < .001) predicted 74% of unfavorable events. The study 
concluded that BNP levels are strong and accurate predictors of cardiovascular 
mortality and early readmission in patients with HF. The authors recommended 
that BNP levels might be used successfully for patient follow-up after an event of 
HF decompensation.  
  Maisel et al. (2004) conducted the Rapid Emergency Department Heart-
Failure Outpatient Trial (REDHOT), and examined the association between BNP 
levels, perceived severity, clinical decision-making, and outcomes (hospital LOS 
and mortality) in CHF patients presenting to the emergency department (ED).  
Physicians were blinded to the actual BNP level and subsequent BNP 
measurements, and patients were followed to 90 days after discharge. Of the 464 
patients enrolled, 90% were hospitalized. The overall hospitalization rate was 
90.3% although physicians intended to admit 68.3%. The ED doctors’ intention to 
admit or discharge a patient had no influence on 90-day outcomes, but the BNP 
level was a strong predictor of 90-day outcome (22%). Findings indicated a 
disconnect between ED physicians’ perceived severity of CHF and severity as 
determined by BNP levels.  Discharged patients were likely to die or be 
readmitted (19 out of 45 or 42.2%) compared to admitted patients (110 of 425 or 
25.9%) within the 90-day follow-up (p = 0.02). The study concluded that BNP 
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levels predicted outcomes and was a valuable tool in making the decision 
whether to admit or discharge a CHF patient.  
  Heidenreich et al. (2004) studied how BNP-guided treatment is associated 
with decreased cost of care. This study evaluated the cost effectiveness of 
screening patients with BNP to classify those with LVD.  The study screened 
1,000 asymptomatic CHF patients with abnormal BNP levels. Those with 
abnormal BNP levels were followed up by echocardiography to assess left 
ventricular function.  Results indicated that such screening increased lifetime cost 
of care ($176,000 for men; $101,000 for women) and improved outcome (7.9 
quality-adjusted life years for men (QALY); 1.3 QALYs for women), resulting in a 
cost /QALY of $22,300 for men, $77,700 for women. The study concluded that 
screening populations with 1% decreased LVD with BNP followed by 
echocardiography may provide a health benefit cost equal to or less than other 
accepted interventions. 
  Mueller et al. (2004) conducted a study on how BNP-guided decision 
making is associated with decreased hospital LOS. In this study, 75% of the BNP 
group were hospitalized as compared to 85% of the standard group (p = 0.0008). 
A cumulative frequency distribution was used to track for time to discharge of 
patients in the BNP group as compared with the control group. Hospital LOS was 
reduced from 11 days in the standard group (n = 227) to 8 days in the BNP group 
(n = 225).  A total cost of care decreased from $ 7,264 to $ 5,410 (p = 0.006).  
Troughton et al. (2000) found that the BNP group had fewer hospital admissions 
as compared to the clinical group (n = 69, 17 vs. 46, p = 0.02).  
 48
  Latini et al. (2002) studied the long-term effects of angiotensin receptor 
blockers (Valsartan) on BNP and norepinephrine (NE). The Valsartan Heart 
Failure Trial randomized 4,284 CHF patients to either Valsartan or placebo.  BNP 
levels were measured at baseline, 4, 12, and 24 months.  In the placebo group, 
BNP levels rose over time; in the Valsartan group, BNP levels showed a 
sustained decrease. Results showed that Valsartan significantly reduced the risk 
for both mortality and morbidity by 13.2%, for hospitalizations for HF by 27.5%, 
but not for mortality alone. BNP was the strongest predictor of outcome 
(hospitalization, death) when compared with other clinical markers (p = .0001).  
  The findings of Richards et al. (2002) supported the relationship of BNP 
levels and CHF hospitalization. The study enrolled 69 symptomatic CHF patients 
(NYHA II-IV) randomized to receive drug treatment guided by BNP or standard 
clinical assessment. Treatment was guided by the use of a treatment target score 
according to modified Framingham criteria of <2. When the target score was < 2, 
medical treatments were intensified until scores were met. Using the t-test 
statistic, the study reported that using BNP levels for decision-making (19 vs. 54 
clinical events) reduced time of first cardiovascular event hospitalization  
(p = .034) and death (p = .049). 
  Cheng et al. (2001) studied a convenience sample of 72 veteran patients 
admitted from March to December 1999. Participants were enrolled to determine 
if BNP level predicts outcomes of patients admitted with decompensated CHF. 
The authors also examined whether an association existed between initial BNP 
level measurement, pre-discharge BNP measurement and outcomes of death, 
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and a 30-day readmission rate. A t-test statistic was used to compare two groups; 
the BNP group and the control group. BNP levels were measured daily. Daily 
BNP levels were drawn within 24 hours after admission and within 24 hours prior 
to discharge or death (in case of death, last drawn BNP levels were considered). 
Of 13 deaths and 9 readmissions, the last measured BNP level was the single 
variable most strongly associated with patients experiencing one of the pre-
specified end points of death in hospital, death within 30 days after discharge, or 
hospital readmission within 30 days. Mean BNP levels were significantly greater 
in patients experiencing end points (1,801 ± 273 pg per ml standard error of the 
mean [SEM] vs. 690 ± 103 pg per ml SEM) compared to patients with successful 
treatment of CHF (p < 0.001). Patients who died or were readmitted had higher 
BNP levels (mean increase = 233 pg per ml, p<0.001) than those who lived or 
were not readmitted (mean decrease = 215 pg per ml). The subgroup of patients 
surviving to discharge, using the NYHA classification, was the most significant 
predictor of readmission (p = 0.0002); discharge BNP was associated with 
readmission within 30 days (AUC (C-statistic) = 0.72, p = 0.02). The last measure 
of BNP was strongly associated with both death and hospital readmission (area 
under the receiver operator curve of 0.73) and therefore suggested that BNP 
levels could be successfully used to guide treatment for patients with 
decompensated heart failure.  
  It is important, therefore, to understand the role of BNP in CHF 
hospitalization for the early detection and identification of CHF symptoms and for 
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potentially reducing hospital admissions, decreasing hospital LOS, and lowering 
healthcare costs.  
Knowledge of BNP Levels Predicting Treatment 
Preclinical recognition of increased BNP levels improves prognosis compared to 
treatment after onset of severe symptoms (Hennekens, 1987). In August 2003, 
the Food and Drug Administration (FDA) approved two indications for BNP as a 
point-of-care rapid assay for the diagnosis of CHF. These included (1) 
distinguishing cardiac cause of acute dyspnea from pulmonary or other non-
cardiac causes and (2) distinguishing decompensated CHF from exacerbated 
chronic obstructive pulmonary disease (COPD).  However, Medicare does not 
reimburse routine use of BNP assays to assess the effectiveness of CHF therapy, 
for the titration of therapy of heart failure, or for prognostic uses (Center for 
Medicare & Medicaid Services, 2003). The ACC/AHA 2005 Practice guidelines 
indicated that high BNP levels are predictive of HF but should be used in 
conjunction with other clinical assessment. The Heart Failure Society of America 
(HFSA) 2006 Practice Guidelines state that BNP levels are not recommended as 
a routine part of HF evaluation for patients at-risk but without signs and symptoms 
of HF. This means that BNP levels are useful in the diagnosis of HF, but 
physicians are cautioned not to depend solely on this laboratory assay but to use 
it as an additive tool in the diagnosis of HF. 
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Studies on Knowledge of BNP Levels Predicting Treatment 
  Aspromonte et al. (2006) evaluated whether BNP levels associated with 
echocardiography would effectively stratify patients with new symptoms as a part 
of a cost-effectiveness program. The study enrolled patients suspected of CHF  
(n = 357) referred to the cardiology clinic by primary physicians. All patients were 
clinically examined. Blood was drawn for BNP levels and a transthoracic 
echocardiography was performed. Findings reported high BNP levels at 469-505 
pg per ml (n = 240) on those diagnosed with HF, compared to those without HF,  
43-105 pg per ml (n = 117, p = 0.001). BNP cut-off level was at 80 pg per ml 
(sensitivity 84%, specificity 91%). The authors’ findings indicated that cost 
analysis at this cut-off level might provide a cost savings of 31%. The study 
concluded that BNP levels drawn from patients suspected of CHF are cost 
effective and are helpful in stratifying CHF patients. 
  Daniels et al. (2006) conducted a multi-center site study to determine if 
there was a disconnect between perceived severity of HF by physicians and the 
severity of HF as determined by BNP levels. Patients (n = 151) were enrolled if 
they were seen, treated, or admitted through the emergency department (ED). 
BNP levels were drawn and treating physicians were blinded to BNP levels. After 
clinical assessment, ED physicians classified the patients according to the NYHA 
functional classifications I-IV. ED physicians were asked whether the initial 
disposition of these patients would warrant hospitalization. Patients were followed 
up after 90 days. Results showed that of 90% of those hospitalized, 32.5% were 
white and 63.4% were black. African Americans discharged from the ED had a 
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higher median of BNP levels compared to white (1,295 vs. 533, p = 0.004). 
African-American HF patients who were discharged had a higher mean BNP 
levels as compared to African-American HF patients who were admitted (1,293 
pg per ml vs. 769 pg per ml, p = .04). This finding was not the same for whites 
(692 pg per ml vs. 533 pg per ml, p = .09). The authors concluded that a 
disconnect in perceived severity of HF and in severity using BNP levels is more 
evident in African Americans. This means that the perceived severity of HF by ED 
physicians did not often correlate highly with BNP levels. In the original REDHOT 
study, patients who were sent home from the ED had higher BNP levels than 
those who were admitted. In this study, BNP levels were stronger predictors of 
outcome than was perceived severity of CHF (Maisel et al., 2004).   
  Mueller et al. (2004) studied the usefulness of BNP-guided treatment in 
ED patients. Participants (n = 452) were randomized to a diagnostic strategy of 
measuring BNP levels (n = 225) or to standardized treatment (n = 227). Of the 
BNP group, 15% required intensive treatment; of the standard group, 24%  
(p = 0.01). The 30-day mortality rates were lower (p = 0.45) in the BNP group 
(10%) than in the standard group (12%). The study concluded that BNP levels 
used with other clinical information improves evaluation and treatment of ED CHF 
patients with acute dyspnea. The mean cost of treatment in the BNP group was 
$5,410 compared to $7,264 in the control group (p = .006).  Using BNP values in 
decision-making decreased treatment cost and reduced hospitalization in the 
treatment group (p = .001). Another purpose of the same study (Mueller et al., 
2006) was to find out the cost effectiveness of BNP-guided testing in the ED 
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patients. Results showed that total treatment cost was significantly reduced in the 
BNP group ($7,930 vs. $10,503 in the control group; p<0.004). The authors 
concluded that BNP guidance is cost effective in patients with acute dyspnea.  
  Ishii et al. (2003) determined whether cardiac troponin T and BNP would 
stratify CHF patients (NYHA Classes III and IV) after initiation of treatment.  
Enrolling 100 consecutively admitted patients, the study included 54 CHF patients 
categorized as NYHA Class III and 46 CHF patients categorized as Class IV.  
Serum cardiac troponin T (cTnT) and plasma BNP were measured on admission 
and then 2 months later when the number of patients classified as NYHA Class III 
decreased to 40 and those classified as Class IV decreased to 3; and 54 patients 
decreased to NYHA Class II.  Using the Mann Whitney U test for continuous 
variables, the results showed a decrease in cTnT (0.023 vs. 0.063) and BNP 
levels (249 vs. 753), significantly improved NYHA functional class (2.5 vs. 3.5), 
and improved left ventricular ejection fraction (13% vs. 12%, p< 0.01) two months 
after treatment as compared to admission. Thus, a combination of both cardiac 
troponin T and BNP-guided level treatments may prove to be highly effective in 
risk stratification.  
  Troughton et al., (2000) reported that pharmacotherapy guided by BNP 
would produce better outcomes than therapy guided by standard clinical 
assessment.  Patients were recruited after hospital admission with 
decompensated CHF. During clinic visits, patients were double-blind randomized 
to treatment guided by BNP measurements or standard clinical assessment. An 
objective scoring system (with a score of 2 or more indicating decompensated 
 54
heart failure) was used. If target scores (less than 2) were not achieved, early 
treatments were intensified according to a rigid predetermined protocol at 2-week 
intervals until target scores were achieved.  Utilizing the Mann Whitney U test, the 
study found a 50% reduction in total cardiovascular events in comparison to the 
control group.  Patients not receiving BNP-guided treatment experienced more 
cardiovascular-event hospitalizations and deaths (78%) than those receiving 
BNP-guided treatment (22%).  Death rates and hospital admissions were less in 
the BNP-guided group than in the clinical group (19 vs. 54, p = .02). Thus, BNP 
became a preventive strategy targeting a more intensive pharmacological 
treatment, allowing for tailored therapy and follow-up of patients (Troughton et al., 
2000).  
Summary 
  In summary, the literature review revealed that QOL is influenced by how 
individuals perceive their life situations. QOL of patients with heart failure is 
affected directly or indirectly by their functional limitations and psychological 
needs. Studies show that physical symptoms of HF such as shortness of breath, 
peripheral edema, and easy fatigability cause functional and social limitations that 
affect the QOL in HF patients. The review of literature suggests that the presence 
of symptoms, severity, and symptom burden such as insomnia and sleep 
disordered breathing are also associated with poor QOL. Clinical studies 
demonstrate that treating the psychological symptoms of depression, having a 
strong social support, finding meaning in life, achieving perceived control, and 
having spiritual faith and beliefs are an integral part of the psychosocial 
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adjustment to any disease condition.                                                                                         
  According to the AHA (2005), HF patients’ frequent and regular hospital 
admissions have a tremendous impact on the economic burden of the healthcare 
system in the United States. The review of the literature supports the view that 
CHF is a chronic debilitating disease that is associated with increased 
hospitalization. Reduction in HF admissions and hospital LOS, therefore, may 
result in lowered social and economic costs and decreased healthcare 
expenditures. Numerous studies indicate that when physicians are aware of 
patients’ BNP levels, HF patients have shorter hospital LOS and fewer hospital 
admissions. BNP is a biomarker that provides a measurable guide in the 
diagnoses of HF. The literature review supports the concept that recognition and 
knowledge of BNP levels during ED visits may be critical for patients to receive 
timely diagnosis and early relief of the symptoms of HF. Current research shows 
that the drawing of blood for BNP levels in HF clinics is not routine, and evidence 
does not support its general use. HF patients may benefit from having BNP levels 
drawn as part of a clinic visit assessment. Therefore, there is a need to examine 
whether knowledge of BNP levels influences physicians’ treatment of HF. This 
study will examine whether physicians’ knowledge of BNP levels and treatment of 
HF at time of clinic visit influences CHF patients’ QOL and hospital LOS. 
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Chapter 3 
Methods 
Introduction 
Chapter 3 outlines the research methods and procedures for this 
study. The discussion of the research design is followed by a description of 
the sample and its inclusion and exclusion criteria. Next comes a 
description of the setting, instruments used, procedures, institutional review 
board (IRB) approvals, and informed consent. Finally the data analysis 
procedures are presented. 
Design 
The research used a randomized controlled trial assigning participants into 
two clinic groups. The participants were randomly allocated to a group, one 
having the physician informed and the other, not informed of patients’ BNP 
levels. The experimental group was composed of subjects whose BNP levels 
were disclosed to the physician. The control group included those subjects 
whose BNP levels were not disclosed to the physician. Subjects were not 
informed of their BNP levels. The specific aims of the study were: (1) to 
determine if physicians’ knowledge of BNP levels would make any difference in 
the quality of life scores between the experimental and control group at 90 days 
and (2) to determine if physicians’ knowledge or lack of knowledge of BNP levels 
at time of CHF clinic visit would affect hospital LOS on all hospital admissions, 
regardless of how many hospital admissions occurred in 90 days.  
Figure 2 illustrates the hypothesized logic model of the relationship of BNP 
levels and hospital length of stay and quality of life. The logic model illustrates 
that knowledge of BNP was the independent variable, and CHF hospital LOS and 
QOL were the two dependent variables of the study.  BNP levels were measured 
using the Triage BNP Immunoassay Kit (Biosite, San Diego, CA), and QOL was 
measured by the Minnesota Living With Heart Failure (MLWHF) questionnaire. 
Hospital LOS was documented on the medical information form, and hospital 
charts were reviewed to verify hospital admission and diagnosis.  
         Input                                        Intervention                                Outcome 
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Figure 2.  Logic model:  Relationship between disclosed BNP levels to 
hospital LOS and quality of life in patients treated for heart failure. 
Setting 
The research took place at Shands Jacksonville Cardiovascular 
Center located at Jacksonville, Florida. The heart failure clinic is located on 
the fifth floor of the Ambulatory Care Center. This Center offers numerous 
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national and international clinical trials and state-of-the-art diagnostic, 
therapeutic, and rehabilitative cardiac services. The cardiovascular center 
includes: examining rooms, stress testing labs, electrocardiographic and 
quantitative 2-D echocardiographic labs, patient and family education 
libraries, catheterization laboratories, a technologically advanced 
observation unit for patients undergoing outpatient heart catheterization, 
and electrophysiology laboratories.  The 24,000-square-foot Center 
annually serves approximately 500 to 600 heart failure patients per year, 
whose estimated ethnic/racial composition is 54% Caucasian, 45% African- 
American, and 1% other minorities.  
The heart failure clinic has a triage/laboratory room, physician 
offices, and nine examining rooms. The clinic schedule for heart failure 
patients was Monday and Friday each week. At times, HF clinics were re-
scheduled randomly according to physician availability. The average 
number of patients seen was approximately 30 to 40 patients a week. The 
clinic is managed by two University of Florida cardiologists, nursing and 
clinical staff, unit secretaries, registration/accounting staff, and a 
receptionist. A total of 15 personnel staff the heart failure clinic. The heart 
failure research director is highly involved with the daily operations of the 
clinic. He is a trained cardiologist specializing in the diagnosis and 
management of heart failure. 
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Population and Sample 
A total of 108 participants were enrolled in the study. The power 
analysis was based upon the effect size of 0.5, which was reported in the 
literature. According to Troughton et al. (2000), the effect of BNP-guided 
treatment of HF had an effect size of 0.5. Combining this effect size with an 
alpha of 0.05 and a power of .80, the projected sample size was 128. The 
target population included patients from the clinic diagnosed with heart 
failure. Participants were included in the study if the following conditions 
were met: at least 21 years old; able to read, write, and speak English; able 
to give voluntary consent; with New York Heart Association (NYHA) 
classifications of II-IV; and with an ejection fraction (EF) of less than 40%. 
Participants were excluded from the study if the following conditions were 
present: co-morbid conditions limiting life expectancy to less than one year 
as determined by the attending cardiologist and a history of acute or 
chronic renal failure as evidenced by serum creatinine of over 2.0.  
                                             Instruments 
The instruments used for the study included the BNP 
Immunoassay Kit, a medical information form, and the MLWHF 
questionnaire. The independent variable, BNP level, was measured using 
BNP Triage Immunoassay Kit (Biosite Co., 2004). Demographic data that 
included age, gender, ethnic background, education, occupation, marital 
status, and insurance payers were documented on the demographic 
information form (Appendix A). Quality of life was assessed by using the 
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MLWHF survey (Appendix B). Hospital LOS was documented utilizing the 
medical information form (Appendix C).  
Independent Variable –  
BNP Rapid Assay 
B-type natriuretic peptide levels are elevated in cardiac disease 
and are sensitive to increased ventricular stretch (Mark & Felker, 2004). 
BNP levels are reflective of left ventricular diastolic filling pressure and 
therefore correlate with pulmonary capillary wedge pressure (Jiang, et al., 
2001; Maisel, et al., 2002; Cheng et al., 2001; Ishii et al., 2003; Tabbizar et 
al., 2002; Anand et al., 2002). Unlike cardiac enzymes that are ordered in 
series, BNP assays are performed on an as-needed basis in hospitals, 
emergency rooms, or clinics. According to the American College of 
Cardiology and American Heart Association Task Force on Heart Failure 
Guidelines (2005), BNP levels greater than 100 pg per ml predict the 
diagnosis of symptomatic heart failure. 
The BNP test, therefore, measures the presence of b-type 
natriuretic peptide levels present in the circulating bloodstream. The test is 
called a rapid assay because it is a simple blood test that can be done at 
the bedside or clinic and takes 15 minutes to complete. BNP testing in the 
outpatient clinic is feasible because BNP testing is not affected by food or 
exercise. It is used when there is a need to have immediate results. BNP 
levels may help diuretic adjustment after discharge, reflect CHF 
exacerbation, or may reflect successful treatment or titration (Maisel, 2002). 
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The two most commonly used criteria for diagnosing heart failure 
are those of the National Health and Nutrition Examination Survey 
(NHANES) and the Framingham criteria (AHA, 2005).  When compared to 
the NHANES and the Framingham criteria for diagnosing heart failure, the 
BNP screening test is more accurate at 83%; the National Health and 
Nutrition Examination Survey (NHANES) showed an accuracy of 67%, and 
the Framingham criterion showed an accuracy of 73% in confirming the 
diagnosis of heart failure (Maisel, 2002).  
The Triage BNP Test (Biosite, San Diego, CA) uses a fluorescence 
immunoassay that measures B-type natriuretic peptide (BNP) in whole 
blood and plasma specimens using trisodium ethylenediaminetetraacetate 
trihydrate (EDTA) as the anticoagulant (Biosite, 2004). In order to satisfy 
Clinical Laboratory Improvement Amendments (CLIA) and Joint 
Commission on Accreditation of Healthcare Organizations (JCAHO) 
standards, three levels of assayed liquid controls were used to verify the 
calibration of the Triage BNP Test throughout the reportable range every 
six months. There is no time to first-result since the BNP immunoassay is 
not an analyzer and not run in batch modes. Calibration of the test was 
done by using the provided assayed controls supplied by Biosite. There 
were five assay controls, and CLIA required doing at least three out of the 
five controls. The lowest and highest controls were used to perform the 
calibration. Controls used should result in numbers not less than 5 pg per 
ml or higher than 5000 pg per ml. 
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The BNP Triage Immunoassay Kit has a reportable range of 5 pg 
per ml to 5000 pg per ml (Biosite, 2001). BNP results less than 100 pg per 
ml are representative of normal values in patients without CHF. BNP 
results higher than 100 pg per ml are considered abnormal and suggestive 
of CHF.  According to Maisel (2001), the mean BNP values for NYHA Class 
I are 152 ±16 pg/ml; for NYHA Class II, 332 ± 25 pg per ml; NYHA Class III, 
590 ± 31 pg per ml; and 960 ± 34 pg per ml for NYHA Class IV. BNP 
results higher than 5000 pg per ml are considered very high values and 
exceed the upper limits of the BNP test. Higher BNP concentrations 
measured in the first 72 hours after an acute coronary syndrome are 
associated with an increased risk of death, myocardial infarction, and CHF 
(Biosite, 2004). 
The BNP Immunoassay Kit uses a sample type of either whole 
blood or plasma drawn in plastic tubes. Sample collection and storage for 
whole blood and plasma is up to 24 hours at room temperature or 2-8 
centigrade degrees in a refrigerator. Reagent stability is good until 
expiration date on the box or up to 14 days at room temperature. The BNP 
analysis is based on the amount of fluorescence the meter detects within a 
measurement zone on the device.  A greater amount of fluorescence 
detected by the meter indicates a higher BNP value (Biosite, 2004).  
A daily quality control (QC) procedure was performed on the BNP 
machine to maintain consistently accurate readings. This was done on on 
heart failure clinic days (Mondays and Fridays) before any participants’ 
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blood was drawn for the BNP test. To run the daily QC, a stimulator chip 
code was inserted into the meter and prompts on the screen were followed. 
A test was run, and a pass or fail result was displayed/printed when testing 
was completed. Biosite provided QC materials containing plasma to run the 
daily QC procedure (Biosite, 2004). 
Performance Characteristics of the Triage BNP Test 
     Linearity of the BNP Triage Immunoassay Kit 
Plasma specimens anticoagulated with EDTA were spiked with 
purified BNP to a final concentration of 5000 pg per ml. Each spiked 
plasma specimen was diluted gravimetrically with unspiked plasma to 
obtain BNP values throughout the range of the Triage BNP Test. Linear 
regression analysis of the data indicated that the assay is linear throughout 
the measurable range of the test (Biosite, 2004).  
     Interfering substances 
              Hemoglobin up to 10,000 mg per dL, cholesterol up to 1,000 mg 
per dL, triglycerides up to 1,000 mg per dL and bilirubin up to 20 mg per dl 
added to plasma concentrations containing BNP did not interfere with the 
recovery of BNP. Hematocrit varied between 27% and 51% with no 
significant effect on the recovery of BNP (Biosite, 2004). 
     Analytical Sensitivity 
              Analytical sensitivity differs from clinical sensitivity; analytical 
sensitivity refers to the test and not to the patient population. Analytical 
sensitivity refers to the lowest value that the test can read that distinguishes 
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from zero (Biosite, 2004). The average 95% confidence limit of the 
analytical sensitivity of the Triage BNP Test was less than 5 pg/mL (95% 
confidence interval 0.2 pg/L to 4.8 pg/ L). Thus, the test cannot be exactly 
zero. Analytical sensitivity or the lowest detectable concentration that is 
distinguishable from zero for the BNP test was determined by testing a zero 
calibrator 20 times each using three lots of reagents and five meters on 5 
days (Biosite, 2004).   
     Analytical specificity 
              Analytical specificity refers to the accuracy with which the test is 
able to detect the correct molecule, BNP (Biosite, 2004). Precision of the 
BNP machine, the use of various pharmaceuticals and the use of blood and 
plasma for drawing BNP levels are discussed as they relate to the 
analytical specificity of the BNP assay. 
     Precision 
             The average within-day and total precision of the BNP assay was 
determined using the ANOVA model by testing control materials that had 
BNP added at concentrations near the decision points of the assay and 
throughout the range of the standard curve. This study was done over 12 
days, testing each control ten times a day.  Each device was read on five 
Triage meters (Biosite, 2004). It is noted that the use of different Triage 
meters does not significantly affect the test precision. Coefficient of 
variation (CV) is equal to the standard deviation multiplied by 100 divided 
by the mean (Hulley & Cummings, 1988). This means that the higher the 
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CV, the less precise the test. As a point-of-care test and the use of an 
immunoassay, the BNP test is considered precise at 10% within the 
National Laboratory Guidelines (Biosite, 2004). Table 2 illustrates the 
coefficient of variation (CV) measures of the BNP test as stated by the 
Biosite instruction manual.  
Table 2  
Coefficient of Variation Measures for BNP Test (Total CV %) 
           Mean  
       (pg per ml) 
            SD 
       (pg per ml) 
                   CV  
                   (%) 
            71.3               7.0                    9.9% 
          629.9             75.5                  12.0% 
        4087.9           500.1                  12.2% 
        Biosite Inc., 2004 
                                                                                                                                             
Test-retest reliability 
              A test-retest reliability of the Triage BNP rapid assay was 
performed for this study. The purpose of performing the test-retest reliability 
was to make sure that the BNP machine produced the same BNP results 
when a participant took the same test twice. BNP-levels results from the 
first and second tests should fall within the coefficient of variation percent 
(CV%) in order to be precise. A test-retest method of the Triage BNP 
Immunoassay Kit was done on 10% (n = 14) of the participants. The CV% 
for this study was 9.3%. Using systematic sampling, every 10th subject had 
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blood tested for the second BNP levels. Only one cubic centimeter (cc) of 
whole blood was drawn; this was sufficient for both the initial BNP test and 
for the test-retest reliability procedure. A detailed description of the 
procedure for performing BNP test is described under baseline data 
collection. 
     Pharmaceuticals 
              Fifty-four drugs, ranging from common acetaminophen to 
angiotensin-converting enzyme inhibitors, diuretics, beta blockers, statin 
drugs, and antibiotics, were evaluated for potential cross-reactivity and 
interference of the Triage BNP Test. Results showed none of the drugs 
interfered with the recovery of BNP; neither did they produce a significant 
response when tested in a specimen not containing BNP. There was no 
significant interference with the BNP measurement and no assay cross-
reactivity (Biosite, 2004). 
     Use of whole or plasma correlation 
              A study comparison performed on EDTA whole blood versus 
plasma showed the correlation data as r2 = .9878, y = 0.925 x +13.439 
(Biosite, 2004). Plasma is indicated by y and whole blood by x (Biosite, 
2004). This means that there is a slight difference in using plasma and 
whole blood, but the correlation is high enough that it does not make any 
difference when the test is run by either whole blood or plasma. For the 
study, whole blood was used to test for BNP levels. 
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     Clinical sensitivity 
              Clinical sensitivity, or sensitivity, refers to the proportion of 
subjects with the disease who have a positive test; it also indicates how 
well a test identifies the disease (Hennekens, 1987). In a study conducted 
by Maisel et al. (2002), using the BNP Triage Immunoassay Kit, the BNP 
cutoff value of 100 pg per mL had a sensitivity of 90%, meaning that 
approximately 90 heart failure patients will test positive for heart failure, and 
10 patients will test false negative.  
     Clinical specificity  
              Clinical specificity, or specificity, refers to the proportion of 
subjects without the disease who have a negative test; it indicates how well 
a test identifies the non-diseased subjects (Hulley & Cummings, 1988). In 
the Breathing Not Properly (BNP) study conducted by Maisel (2002), using 
the BNP triage Immunoassay Kit, the specificity was 76% with a predictive 
negative value of 90% (cut-off value of 100 pg / mL).  
     Relative risk  
              Relative risk compares the incidence of disease among exposed 
people with the incidence of disease among non-exposed people by means 
of a ratio (Hennekens, 1987). A BNP level of 230 pg per ml is correlated 
with a relative risk of 7.0 (Maisel, 2002). A relative risk of 7.0 means that 
the incidence of heart failure is seven times as high in patients with heart 
failure as in those without heart failure. Table 3 illustrates comparison 
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decision statistics using the BNP Triage Immunoassay Kit as reported from 
several studies. 
  Table 3  
  Summary of Studies Utilizing the BNP Triage Immunoassay Kit  
  Study   BNP  
 cut-off    
 (pg per ml) 
Sensitivity 
    (%) 
  Specificity
    (%) 
  PPVa
   (%) 
  NPVb
   (%) 
Diagnostic 
Accuracy 
 (%) 
  Maisel et 
  al.(2002) 
n = 1,586 
  100 
    50 
  90 
    - 
 76 
   - 
    96 
 
83 
Wiezorek  
et  al. 
(2002) 
  n = 1050  100  82  97 
   
 
 
93 
  Dao et 
 
  (2001) 
  n = 250 
 100  94  94     92    96 
 
 
94 
 
  Morrison  
  et al. 
  (2002) 
  n = 321 
    
   94 
 
 86 
 
 98     98 83 
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Note. aPPV = positive predictive value    b NPV = negative predictive value  
Demographic Data Form 
The demographic form ( Appendix A) created for this study was a 
ten-item survey used to collect information that could be related to the 
outcome variables. These variables included the following: age, gender, 
marital status, ethnic background, education, occupation, and insurance 
payers. These factors were documented to determine the relationship 
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between these variables and BNP levels, CHF hospital LOS, and quality of 
life.  
Dependent Variables 
The Minnesota Living with Heart Failure Questionnaire                       
(Appendix B) was utilized to measure the dependent variable of quality of 
life. The medical information form was used to abstract patients’ hospital 
length of stay.  
Description of the Minnesota Living With Heart Failure Questionnaire  
The dependent variable quality of life (QOL) was measured by the 
Minnesota Living With Heart Failure (MLWHF) questionnaire (Rector, 
Kubo, & Cohn, 1987). This was a 21-item, self-administered questionnaire 
with subscales covering physical, socioeconomic, and psychological 
impairments among CHF patients. The instrument was developed to 
systematically and thoroughly evaluate patients’ perceptions of the effects 
on daily life of heart failure and its treatment. Patients ranked specific 
impairments, on a scale from 0 (best) to 5 (worst), according to how CHF 
prevents them living as they would like, in other words, ranking each 
impairment’s significance or difficulty. The MLWHF questionnaire was 
scored by adding all the numbers circled by the participant. The higher the 
patient’s score, the greater the limitations, with the worst possible score 
being 105 (Rector, Kubo, & Cohn, 1987). 
The questionnaire contained total, physical, and emotional 
subscales. These subscales included groups of questions that contained 
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similar information. Responses to questions 2 (rest during the day), 3 
(walking and climbing stairs), 4 (working around the house), 5 (going away 
from home), 6 (sleeping), 7 (doing things with others), 12 (dyspnea), and 
13 (fatigue) were highly correlated to the physical dimension. Questions 17 
(feeling burdensome), 18 (feeling a loss of self control), 19 (worry), 20 
(difficulty concentrating and remembering), and 21 (feeling depressed) 
were highly correlated to the emotional factor (Rector et al., 1992). The 
physical subscale had 8 items, the emotional subscale had 5 items, and a 
total of 21 items were used in the study. 
Reliability and Validity of the MLWHF 
A study conducted by Riegel (2002) reported that total QOL scores 
among discharged HF patients improved after receiving intensive 
interventions. After 1 month, 3 months, and 6 months of intensive 
treatment, the study showed significant differences in quality of life scores 
among treatment dose groups (F = 3.43, df = 9,579, p<.001 ; F = 7.45, df = 
9,579, p <0.001; F = 4.86, df = 9,768, p<.001, respectively). The trial 
concluded that the MLWHF questionnaire was sensitive to major 
differences in symptom severity but not to subtle signs and symptoms of 
heart failure. A recommendation of the study was to caution researchers 
that the instrument was best used with a control or comparison group 
(Riegel, 2002). The alpha coefficients for total QOL scores at each time 
period ranged from 0.92 at baseline to 0.96 at one month. The alpha 
coefficient for the physical subscale was .92 at baseline and .95 at one 
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month; the alpha coefficient for the emotional subscale was .87 at baseline 
to .92 at one month (n = 1,136). 
 In another study by Rector et al. (1987), 83 patients with left 
ventricular dysfunction completed the MLWHF.  Baseline variability was 
assessed by a second administration after 21 days.  Statistical analysis on 
the differences and weighted kappas provided evidence for reliability, and 
internal consistency of the MLWHF questionnaire was examined using 
Spearman rank order.  Validity was assessed by correlating the MLWHF 
scores with the response to, “Overall, how much did your heart failure 
prevent you from living as you wanted the past month?”  The correlation 
between the NYHA classification and the patients’ rating on the MLWHF 
questionnaire was statistically significant (r = 0.80, p <0.01). This 
association suggests that the questionnaire is a suitable representation of 
functional impairment. For this study, the MLWHF score reliably measured 
QOL among CHF patients with a weighted kappa of 0.84 between the 
individual items and the total score.  Thus, the MLWHF questionnaire 
showed potential to increase knowledge of CHF symptoms and effects of 
medical interventions. 
In 1992, Rector and Cohn evaluated the quality of life of 198 
ambulatory patients using the MLWHF questionnaire. The inter-item 
correlations of the questionnaire identified categories of questions for both 
physical and emotional scores. Test–retest reliability was high for the total 
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score: r = 0.93, physical: r = 0.89; and emotional: r = 88. Cronbach’s alpha 
was 0.94 (total), 0.94 (physical), and 0.90 (emotional).  
            In a study conducted by Gorkin et al. (1993), psychometric 
properties of the baseline measures used in the Studies of Left Ventricular 
Dysfunction (SOLVD) trial were analyzed. The measures included the 6-
minute walk test, dyspnea scale, MLWHF, physical limitations, 
psychological distress, and health perceptions. Researchers concluded that 
the internal consistencies of the self-report instruments were high, with the 
exception of the health perceptions of NYHA Class II or III patients. The 
MLWHF questionnaire revealed a Cronbach alpha of 0.95 for 135 NYHA 
Class I patients and an alpha of 0.94 for 123 NYHA class II and III patients. 
Table 4 illustrates the reliability of the MLWHF questionnaire as presented 
from several studies.  
Table 4  
Reliabilities of the MLWHF Questionnaire 
           Study   Sample Size     NYHA Class    Reliability 
Rector et al. (1992) 198   III α = 0.94 
 
Rector et al. (1987)    83     I-III   Weighted kappa 
       0.84 
             
Gorkin et al. (1993) 135 
123 
I 
      II-III 
α = 0.95 
α = 0.94 
 
Reigel et al. (2002) 1136    -- α = 0.92 
Note. NYHA = New York Heart Association 
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Hospital Length of Stay  
Hospital length of stay (LOS) was tallied for each admission after 
the baseline clinic visit. The medical records of all participants who 
reported a hospitalization were immediately reviewed by the primary 
investigator (PI) to see whether the primary discharge diagnosis was 
reported as CHF.  The PI reviewed hospital charts to examine whether 
patients were admitted because of CHF diagnostic symptoms and/or other 
causes. Only the CHF admissions were of interest to this study. The 
frequency of hospital admissions were monitored and documented in the 
medical information form for up to 3 months and were reviewed for the 
number of days patients stayed in the hospital. Portions of the day were 
considered as one day of hospital stay. 
Medical Information Form 
The medical information form ( Appendix C)developed by the (PI), 
is a three-item survey used to document NYHA classifications, hospital 
admissions and dates (if any), diagnoses, and number of days participants 
stayed in the hospital.  
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Summary of Reliabilities of Instruments 
Table 5  
Summary of Reliabilities of Instruments Used in the Study 
Variables  Number 
of  
items 
Instruments Reliabilities Range of 
scores 
BNPa    1 Triage BNP       Sensitivity =  95%  
Specificity =  98%    
PV-           =  96%       
Standard Error = 4% 
                                    
5 to 
5000 pg / ml 
QOLb    21 MLWHFc α = 0.95 
 α = 0.94                      
0-105 
Hospital  
LOSd
   10 
     
    3 
Demographic 
Form 
Medical   
Information    
Form 
 NA 
 
 NA 
 
      Note. aBNP = B-type natriuretic peptide  bQOL = quality of life  
 cMLWHF = Minnesota Living With Heart Failure   dLOS = Length of stay;  
 
Procedures 
Approvals 
Permission to use the Minnesota Living With Heart Failure 
Questionnaire was obtained from the University of Minnesota, which 
provided a waiver for research purposes for one year Approval to conduct 
the study and recruit participants was obtained from both the Institutional 
Review Boards (IRBs) of the University of South Florida and the University 
of Florida, Shands Jacksonville A letter of support from Shands Heart 
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Failure Clinic Medical Director was also provided (Appendix D). The 
informed consent form (ICF) and any changes made thereafter had to be 
approved by both IRB institutions. A continuing review report was filed and 
had to be approved by both IRB institutions prior to the expiration date of 
the study.  
  Recruitment 
Upon approval of the IRBs and Health Insurance Patient Portability 
Act (HIPPA) compliance Board, a research assistant employed by Shands 
Jacksonville reviewed the CHF clinic schedule and patient charts and then 
screened eligible participants for the study. During the clinic visit, eligible 
participants were referred to the Principal Investigator (PI). Prior to being 
seen by the physician, the participant was approached by the PI in the 
waiting room and taken to a consultation room for privacy. The purpose of 
the study was explained thoroughly and ample time given for any 
questions regarding the study to be answered. Potential risks and benefits 
were explained to the patient. If the patient agreed to participate, the 
participant signed the informed consent form that incorporated the HIPPA 
authorization form (Appendix E).   
The average number of heart failure patients scheduled on 
Mondays and Fridays varied from 16 to 20 patients. The PI saw 
participants on both days.  Data collection for each participant took no less 
than 30 to 45 minutes. The participant signed two copies of the informed 
consent, which included a contact number for the PI.  A leaflet of frequently 
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asked questions (FAQs) regarding the study was given to each patient 
(Appendix F). One copy of the informed consent was given to the 
participant, and the other copy remained in the participant’s clinic chart. 
The PI explained to the participants the importance of completing the 
study. Participants were informed that once the study was completed, the 
results were available to them if they so desired. Additionally, participants 
were assured that participation in the study would not increase their 
medical costs. 
The participant, or the participant’s family member, was asked to 
contact the PI in the event of any hospitalization within 90 days from time 
of clinic visit. Once the PI had information on participants’ hospitalization 
via telephone or mail, the PI reviewed the hospital chart to verify if the 
hospitalization was due to CHF. Subjects were informed that participation 
was voluntary, that they could withdraw from the study at any time, and 
that all data collected were kept confidential.  
Random Assignment 
Participants were randomly assigned to either the experimental 
(BNP) or control group after agreeing to take part in the study.  It is 
important that the PI and physician not know in advance whether a patient 
is assigned to the BNP or the control group. Participants were randomized 
by the PI using randomization with concealment using the following 
process: To prevent bias, patient treatment allocation was done by the 
Statistical Analysis System (SAS) (SAS Institute Incorporated, 2001) based 
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on a computer generated table of random numbers, using a syntax to allow 
random allocation. Numbers were printed, cut apart, and placed inside 
identical opaque envelopes and then sealed. The envelopes were 
numbered from 1 to 140 and stacked in numerical order.  The original table 
of random numbers was destroyed. The PI was not able to anticipate into 
which group the next subject would be assigned. This randomization with 
concealment provided initial blinding of group assignments to the 
researcher.  After eligibility was assessed and consent was obtained, each 
participant took an envelope from the top of the stack. Following 
assignment to treatment condition, all the envelopes had subjects’ names 
written on the outside and were kept in a locked cabinet.  
Baseline Data Collection 
The PI used a consultation room near the waiting room as a 
private area to talk to the participant regarding the study, have the 
informed consent signed, and the survey completed by the patient. The PI 
assisted with the completion of the QOL survey if the patient verbalized the 
need for help. The consultation room was equipped with a table and chair 
so that participants had space to complete the questionnaire.  Blood for 
BNP levels was drawn by the PI and analyzed at point-of-care prior to the 
patient being seen by the physician. Syringes, tubes, pipettes and the BNP 
machine were available on site for drawing BNP levels.  
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Procedure for Completing MLWHF Questionnaire 
The participant self-administered the MLWHF questionnaire, 
unless assistance was requested. The PI explained to the participant the 
importance of completing the MLWHF questionnaire again in 90 days. The 
participants read and responded to all 21 questions and was asked to rank, 
on a Likert-type scale (0-5), each specific impairment according to how 
heart failure had affected their lives during the past month. If a participant 
was not sure an item applied or if an item was not related to heart failure, 
then the participant was directed to circle 0 (No). If an item did apply, then 
the patient was directed to circle a number from 1 (very little) to 5 (very 
much). The total scores indicated the difficulty or importance of the 
impairment. Participants completed the questionnaire prior to any 
assessment or physician interaction. 
Procedure for Performing BNP Test 
Prior to enrolling participants in the study, the PI was certified in 
obtaining BNP levels utilizing the Triage BNP Immunoassay Kit. Using 
sterile technique, the PI drew one cc of whole blood by venipuncture 
collected into a 1-cc tube containing potassium EDTA and measured with a 
fluorescence immunoassay (BNP Triage Immunoassay Kit). The blood was 
mixed gently by inverting the tube several times before transferring the 
blood to the test device. The specimen was added to the sample port of 
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the test device with a transfer pipette designed to deliver 250 ul to the test 
device.   
After the specimen was added, the device was inserted into the 
Triage meter. The meter was programmed to automatically perform the 
BNP analysis after the sample had reacted with the reagents within the 
BNP device. The PI was responsible for collection and disposal of all data 
and blood drawn. Used needles, tubes, and syringes were disposed of in a 
sharps container located inside the laboratory. Blood levels for BNP were 
drawn following completion of the survey. BNP blood levels were drawn 
only once. The physician involved in the study was not given the BNP 
results of participants in the control group. For those in the BNP group, the 
physician was informed of BNP levels by the PI handing him the BNP 
results generated from the Triage BNP Immunoassay Kit when the 
experimental participant entered the examining room. Results were 
documented on the demographic data information form and destroyed. 
Results of BNP levels were not documented in the patient records. On any 
given clinic day, only the PI and one physician exposed to the experimental 
subject had access to the results of the BNP levels. The PI documented 
the BNP level results on the medical information form. Participants were 
not informed of their BNP levels. 
The PI did not inform the physician of BNP levels if he was seeing 
a patient in the control group even if an extremely high level was obtained. 
Treatment and management of CHF patients was guided at this facility 
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using HF guidelines. Currently, BNP testing is not part of routine heart 
failure guidelines (HFSA, 2006). Therefore, the withholding of extremely 
high BNP levels was ethical.  
Follow-Up 
Following the clinic visit and examination of the participant, the 
clinic staff scheduled the next study visit appointment in approximately 90 
days. If the physician requested to see the patient prior to 90 days, this 
was considered a clinic visit—not a part of the study. Every effort was 
made to ensure that the participant came back in 90 days to complete the 
MLWHF survey. The PI contacted the participants via telephone once a 
month, for 3 months to ensure that every CHF hospital admission and 
hospital LOS was known. Three monthly letters were sent inquiring if there 
had been any hospitalizations within the past month, and if so, the place of 
admission, date of admission, and number of days the patient stayed in the 
hospital. Once the PI had information on participants’ hospitalization via 
telephone or mail, the PI reviewed the hospital chart to verify whether the 
hospitalization was due to CHF.  
Ninety days after enrollment in the study, the participants again 
completed the MLWHF questionnaire at the clinic, and the PI completed 
the medical information form to verify whether participants had any 
previous hospital admissions. If unable to reach the participants, the PI 
contacted the alternative contact numbers. In the event that the PI was not 
able to contact anyone, a telephone message was left for the participant to 
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call the PI regarding the survey. Within 90 days plus minus 7 days after the 
baseline clinic visit, if attempts to contact the participant and to do the 90-
day follow-up interview were unsuccessful, then the patients were 
considered lost to follow-up.   
Data Management 
Demographic and medical information used computer generated 
random codes to protect personal identifiers. A master file with names was 
kept and locked in a secure location in the physician’s office. Only the PI 
and supervisors had access to this information.  To ensure patient 
confidentiality, the PI entered all completed surveys, the demographic and 
medical information form, and BNP results into an Excel program.  After 
data collection was completed all identifiers were deleted and destroyed. 
Per IRB protocol, the quality of life questionnaire, demographic, and medical 
information forms are to be kept for 5 years, and study findings will be 
available to participants upon request. 
Data Analysis 
Data were analyzed using Statistical Analysis System (SAS).  A 
confidential, password-secured database was used for data entry, 
management, and data analysis. Frequency distributions of the data were 
used to check for missing values, outliers, inconsistencies. Descriptive 
statistics of the data were provided. An independent t-test was used to 
compare means of QOL scores between the experimental group and 
control group at baseline as well as at 90 days. Bivariate correlations were 
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done among the independent and dependent variables. BNP data were log 
transformed as necessary. Results of the study were reported as 
aggregate numbers, and participants were not identified. 
Hypothesis 1: It was hypothesized that clinicians’ knowledge or lack of 
knowledge of BNP levels at the time of the baseline clinic visit would make a 
difference in the quality of life scores between the experimental and the control 
group at 90 days. An independent t-test was used to examine the relationship 
between experimental and control groups and quality of life scores at 90 days.                         
Hypothesis 2: It was hypothesized that clinicians’ knowledge or lack of 
knowledge of BNP levels at time of CHF clinic visit would affect hospital 
LOS on all hospital admissions of CHF patients within 90 days. An 
independent t-test was used to examine the difference in the mean LOS 
between the experimental and control groups.                                                                    
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Chapter Four 
Results 
This chapter presents the results of this study on the effects of clinic 
physician knowledge of BNP levels on participants’ quality of life at the 90-day 
follow-up.  Preliminary analyses are discussed. These included bivariate 
correlations, checking normality distributions, checking for errors in data entry, 
missing data or outliers. This is followed by the discussion of the demographic 
characteristics and clinical profile of the participants. Next, the statistical analyses 
are discussed in depth, and outcomes for each hypothesis are presented. 
Procedure                                                                                                                                     
 Participants were recruited by the PI from a heart failure clinic in Northeast 
Florida, where 112 subjects were assessed for eligibility. Two potential 
participants were excluded because of high serum creatinine levels, and two 
refused to participate. Enrollment spanned from October 2005 to August 2006, 
and the 90-day follow-up period was completed inn November 2006. The 
intended number of participants to be enrolled was 62 per group for a total of 124 
for both groups. Because of staffing and clinic scheduling issues, such as 
decrease in the frequency of clinic days, fewer patients were enrolled in the study 
than intended. After enrolling patients with due process, questionnaires were 
distributed by the PI. Completion of the questionnaire took an average of 15 
minutes. The survey consisted of 10 demographic questions and 21 QOL survey 
questions. 
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The next step in the procedure was for the PI to draw blood. The blood 
was processed according to the procedure described in Chapter 3 (Procedure for 
Performing the BNP Test). After blood was drawn, a physician examined each 
participant. To minimize error, only one physician performed all the patient 
assessments.                                                                                                            
 The participants were then allocated to either the control group or the 
experimental group. Randomization was done by a random number generator. 
The participants and the physician were blinded to the randomization status. 
After randomization, the BNP level results for those in the experimental group 
were given to the physician. The physician did not receive the BNP results for the 
control group.                                                                                                                                  
Sample                                                                                                                                   
 A total of 108 participants completed the Minnesota Living with Heart 
Failure questionnaire and had their BNP levels blood drawn at baseline. Of the 
108, 57 (53%) participants were assigned to the experimental group and 51 
(47%) participants to the control group at time one (baseline). At time two (follow-
up), 16 participants did not complete the study. Of these, 10 (15%) left the study 
and 6 (5%) died. Of the 10 who left the study, 6 were from the experimental 
group and 4 were from the control group. This left 50 participants in the 
experimental group and 42 participants in the control group, a total of 92 
participants who completed the study at 90 days.                                                
 Due to the concerns about the effects of attrition, data were examined for 
those who did not complete the study. T-test analyses between completers and 
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non-completers showed that there were no significant differences in age, BNP, 
ejection fraction, QOL or the physical and emotional subscales at baseline. 
Therefore, it appears that the loss of these patients did not affect the overall 
outcome. Figure 3 illustrates the trial sample flow diagram. 
Figure 3.  The flow of participants through the trial. 
Enrollment (n = 108) 
Excluded  
(n = 4) 
Not meeting 
inclusion criteria  
(n = 2)                    
Refused to 
participate  
(n = 2) 
Total allocated  
(n = 108) 
Screened for eligibility         
        (n = 112) 
 
 
 
       
 
 
 
 
 
 
Allocated to Control 
(n = 51) 
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Description of Baseline Demographic Characteristics  
 The results for the demographic data are discussed next for the total 
sample (N = 92). Demographic data were collected to include the following 
characteristics: [a] age, [b] ethnicity, [c] gender, [d] education level, [e] insurance 
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payers, [f] marital status, and [g] occupation. All participants completed their 
demographic forms at baseline. Data analysis was conducted, and frequency 
distribution of values of each variable was performed. Utilizing the frequency 
distributions was helpful in examining missing data or revealing the number of 
missing values for each variable that may be due to problems in data collection. 
Patient demographics and clinical profile at baseline were compared for 
equivalence between the two groups by an independent t-test and X2 as 
appropriate (SAS Institute, Version 8.2, Gary, North Carolina, 2001). A  X2 was 
used to analyze the categorical/nominal variables of gender, ethnicity, marital 
status, occupation, education, insurance payers and NYHA classification.  
The independent t-test was used to analyze the continuous variables of 
age, ejection fraction, BNP levels and QOL scores. The four assumptions of the 
t-test which include independence, scale of measurement used, normality, and 
homogeneity were used to validate whether the data met the criteria for using the 
independent t-test. The BNP values were highly skewed. They ranged from 9 pg 
per ml to 5000 pg per ml at baseline. The mean was 458 pg per ml (SD = 759). 
However, the mode was 101 pg per ml; this showed the effects of the outliers of 
the mean. Of the total sample, 31% had BNP values of less than or equal to 101 
pg per ml, and 59% had values ranging from greater than 101 pg per ml to 1000 
pg per ml. The remaining 10% (n = 10) had BNP values ranging from 1110 pg 
per ml to 5000 pg per ml. These last ten data drastically affected the mean; 
therefore, the mode has been reported. Because of the skewness, it was 
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deemed necessary to do a log transformation of the BNP value before using it in 
statistical analyses.   
The demographic and clinical characteristics of the experimental group  
(n = 50) and the control group (n = 42) at baseline are summarized in Table 6. 
There were no significant differences by group in gender, ethnicity, marital status, 
education, occupation, or insurance payers. Additionally, there were no 
significant differences on the clinical profile between groups with regard to age, 
ejection fraction, and BNP levels. Therefore, random assignment of study 
participants appeared to successfully minimize differences between the groups at 
baseline.  
Table 6 
 Baseline Demographic and Clinical Characteristics of Patients by Group 
Note. *SD = Standard Deviation 
       Variables    Experimental    
Group 
       n = 50 
     Control  
      Group 
       n = 42 
 P value 
Age  
     Mean ±   SD* 
          
     63.3±11.5 
        
     65.4±13.4 
     
   .410 
 
Gender (%) 
      Female 
      Male 
 
         24 (48%) 
         26 (52%) 
  
       18 (43%) 
       24 (57%) 
 
 
   .621 
 
Ethnicity (%) 
     African American 
     Caucasian 
     Asian 
 
         26 (52%) 
         23 (46%) 
           1 (2%) 
 
       23 (55%) 
       19 (45%) 
         0 (0%) 
  
 
 
   .645 
Marital Status (%) 
     Single 
     Married 
     Divorced 
     Widow/Widower 
 
           3 (6%) 
         19 (38%) 
         14 (28%) 
         14 (28%) 
 
         7 (17%) 
       16 (38%) 
         8 (19%) 
       11 (26%) 
 
    
   .364 
 Occupation (%)                     
      Retired 
      Disabled 
      Working 
 
         36 (72%) 
         12 (24%) 
           2 (4%) 
 
       27 (64%) 
       10 (24%) 
         5 (12%) 
 
 
   .354 
 Education (%) 
     <High school 
     High school 
     Some college 
     4 Year Degree 
     Masters Degree 
     Doctoral Degree 
 
         13 (26%) 
         19 (38%) 
         12 (24%) 
           5 (10%) 
           1 (2%) 
           0 (0%) 
 
       10 (24%) 
       17 (41%) 
         7 (17%) 
         6 (14%) 
         1 (2%) 
         1 (2%) 
 
 
   
 
   .816 
    
 Insurance Payers (%) 
     Private Insurance 
     Medicare/Medicaid 
     Tricare Military 
     Shands Card 
 
           4 (8%) 
         43 (86%) 
           0 (0%) 
           3 (6%) 
 
         7 (17%) 
       32 (77%) 
         2 (4%) 
         1 (2%) 
 
 
   .189 
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Table 6 (continued) 
 
       Variables    Experimental    
Group 
       n = 50 
     Control  
      Group 
       n = 42 
P value 
 NYHA Classification a 
      NYHA II 
      NYHA III 
 
        18 (36%) 
        32 (64%) 
 
       12 (29%) 
       29 (71%) 
 
 
   .496 
 
 Ejection Fraction (%) 
      Mean ± SD* 
 Serum Creatinine (mg/dl) b
      Mean ± SD 
 
        27.5 ± 7.3 
         
        1.2 ± 0.37 
 
       25.9 ± 9.4 
        
       1.0±  0.40 
 
   .385 
 
    
   .054 
BNP levels(pg/ml) c
  LogBNP levels (pg/ml) 
      Mean  ± SD* 
       407 ±  713 
        4.9 ± 1.44 
       452± 598 
       5.4 ± 1.30 
   .744 
   .131 
Note. *SD = Standard Deviation        a NYHA = New York Heart Association 
Classification    bmg/dl = milligrams per deciliter    c BNP = b-type natriuretic 
peptide; measured in picograms per milliliter (pg/ml)                                              
 
        The mean age for the total sample was 64.5 years (range 24-94 years,  
SD = 12.4, N = 92). By racial identity, 49% were African American, 42% were 
Caucasian, and 1% was Asian. There were more married participants in both the 
experimental and control groups (n = 35, 38%) than single (n = 10, 11%), 
divorced (n = 22, 24%), or widowed/widower (n = 25, 27%).  
More of the total sample completed high school (39%) than did not (25%). 
Additionally, 36% had some college. Of the total study sample, 68% were retired, 
24% were disabled, and 8% were employed. The majority of the study 
participants from both groups had Medicare and Medicaid insurance coverage (n 
= 75, 82%), private insurance (n = 11, 12%), military insurance (n = 2, 2%) and 
Shands Clinic card (n = 4, 4%).  
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Description of Baseline Clinical Profile of the Participants (N = 92)  
For both study groups, the majority (67%) were classified as NYHA III 
and, 33% were classified as NYHA II. The median and the mode for the total 
distribution were both 3.0. The NYHA IIIB were coded as NYHA III for statistical 
purposes. Of particular interest, the NYHA classification was only weakly 
correlated with BNP levels (r = .25, p = .009) and the log BNP levels (r = .22,  
p = 0.03).  
Data on both the ejection fraction and serum creatinine levels were 
obtained within one year from office visit. The overall mean ejection fraction for 
this sample of HF patients was 26.7% (SD = 8.3, median = 28.0, mode = 30). 
The overall mean serum creatinine levels for the total sample was 1.1 milligrams 
per deciliter (mg/dl) (SD = .39, median = 1.0, mode = 0.8). Again, the mean BNP 
was 458 pg per ml, and the mode was 101 pg per ml. In summary, participants 
had a poor ejection fraction and normal serum creatinine levels as required by 
the inclusion criteria. However, they also had BNP levels that barely crossed the 
threshold for heart failure.  
Description of Dependent Variables at Baseline                                                                      
         Quality of life was measured using the Minnesota Living With Heart Failure 
questionnaire. The questionnaire had a total of 21 questions and two subscale 
scores. The physical subscale dimension score consisted of items 2-7, 12, and 
13. The emotional subscale dimension score consisted of items 17-21. The total 
QOL score ranged from 0-105; the total physical subscale score ranged from 0 to 
40; and the total emotional subscale score ranged from 0 to 25 (Rector et al., 
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2002). The remaining 8 questions (range of 0-40) consisted of general questions. 
An independent t-test of the QOL variables demonstrated equivalence at 
baseline. The mean scores for QOL (overall, physical, and emotional) are 
summarized in table 7.  
 Table 7 Baseline Descriptives and Reliabilities of QOL Scores by Group 
 Note.  aMLHFQ = Minnesota Living With Heart Failure Questionnaire                                     
bmin-max = Minimum and maximum scores 
Variables 
 
MLHFQa, 
  Overall 
MLHFQ, 
  Physical 
MLHFQ, 
  Emotional 
Experimental Group  
(n = 50) 
mean ± SD 
median 
mode 
min-max b 
 
 
 
45.9 ± 29.8 
48.0 
13.0 
  3.0-101 
 
 
19.7 ± 13.0 
20.5 
  0.0 
  0.0 - 40 
 
 
9.76 ± 7.91 
9.5 
0.0 
0.0 -25 
Control  
Group (n = 42) 
mean ± SD 
median 
mode 
min-max 
 
 
 
48.6 ± 29.3 
53.0 
  6.0 
11.0-93 
 
 
21.1 ± 14.2 
23.5 
  0.0 
  0.0 - 40 
 
 
11.2 ± 8.37 
10.5 
  0.0 
  0.0 -24 
Cronbach’s alpha  
 
 
0.94 
 
0.95 
 
0.89 
  t value 
 
0.60 0.49 0.90 
  P value 
 
0.54 0.62 0.37 
Bivariate correlation was examined next. As expected, the data revealed 
an inverse relationship between ejection fraction and BNP levels  
(r = -0.28, p = .006). However, the magnitude was not as strong as expected. 
That is, participants with the lower ejection fractions demonstrated higher BNP 
levels. There was a direct relationship between NYHA classification and QOL. As 
NYHA increased, the QOL score increased; this demonstrated a corresponding 
deterioration in the quality of life. There was a weak but significant correlation 
between NYHA and BNP levels (r = .23, p = 0.02). Based upon literature findings 
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from larger sample sizes, it was anticipated that the correlation would be stronger. 
Table 8 summarizes the bivariate correlations among the variables. 
Table 8 
Bivariate Correlational Analysis of Baseline Variables 
  
Bivariate 
Variables 
(N = 92) 
QOL 
Baseline 
BNPL  Age Ejection 
Fraction 
Serum 
Creatinine 
NYHA 
 
QOL 
Baseline 
   
 
 1.00 
     
 
BNPL 
   
  0.25** 
 
 1.00 
    
 
Age 
  
-0.09 
 
 0.21* 
 
1.00 
   
 
Ejection 
Fraction 
 
  
-0.14 
 
 
-0.28***
 
 
0.23* 
 
     
   1.00 
  
 
Serum 
Creatinine 
 
   
 0.10 
 
  
 0.22* 
 
 
0.16 
 
    
  -0.07 
 
      
   1.00 
 
 
NYHA 
  
 0.50*** 
 
 0.23* 
 
0.00 
    
  -0.12 
      
   0.16 
 
1.00 
Note.  P value = *0.05, **<0.01, ***<0.0001 
 
 
Discussion of Results by Hypotheses at the 90-Day Follow-Up 
 
Research Hypotheses:  
Hypothesis 1: It was hypothesized that clinicians’ knowledge or lack of 
knowledge of BNP levels at time of clinic visit would make a difference in the 
quality of life scores between the experimental group and the control group at 90 
days. An independent t-test between experimental and control groups was used 
to compare mean QOL scores at 90 days. Based on the results of the t-test, 
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there was no significant difference in the QOL scores at 90 days (t = -0.79, df = 
90, p = 0.43). Table 9 summarizes the results of the two groups at 90 days. 
Table 9 
Comparison of QOL Score Means by Group at 90 Days  
Variables Cronbach’s 
alpha 
Experimental 
Group 
90 days 
n = 52 
(mean ±  SD) 
Control  
Group 
90 days 
n = 40 
(mean ± 
SD) 
    t  
Value 
    p  
Value 
MLHFQ, 
overall 
 
0.94 
37.5 ±  29.8 32.7 ± 27.9 -0.79  0.43 
Note. MLHFQ = Minnesota Living With Heart Failure Questionnaire 
 Therefore, physician knowledge of BNP levels at time of clinic visit did not 
make a difference in QOL scores at 90 days for either group. It was noted that 
QOL scores went down for each group; this indicated an improvement of their 
overall QOL at 90 days. However, this improvement was equal for both groups. 
The pre and post paired t-test for the experimental group was significant  
(t = .5.07, df = 90, p = .001). For the control group the pre and post t-test was 
significant as well (t = 4.62, df = 41, p = 0.00). These findings will be discussed in 
depth in the next chapter. Hypothesis one was not supported. 
Hypothesis 2: It was hypothesized that clinicians’ knowledge or lack of 
knowledge of BNP levels at the time of CHF clinic visit would affect hospital 
length of stay (LOS) on all hospital admissions of CHF patients within 90 days. 
Portions of the day were considered as one hospital day.  The experimental 
group had a total of 9 participants who were admitted for heart failure for a total 
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of 31 hospitalization days within the 90-day follow-up period. The control group 
had a total of 2 participants who were admitted for heart failure for a total of 6 
hospitalization days within the 90-day follow-up period. An independent t-test 
showed that there was no significant difference in the mean LOS (t = 1.10, df = 
90, p = ns). Table 10 displays the number of hospital days per group assignment. 
Table 10  
Hospital Length of Stay by Group Assignment                                                                              
Group Number 
of 
Patients 
Admitted 
(n = 11) 
  Admission Rate 
Percent            
(%) 
 
Total Days 
In Hospital 
Mean Hospital 
LOS 
Experimental 
Group (n=50) 
      9        18            31      3.4 
 
Control 
Group (n=42) 
      2          5              6      3.0 
Note. LOS = length of stay 
Ancillary Findings  
     Mortality                                                                                                                                   
          There were a total of six deaths between enrollment and the 90-day follow-
up. By the 90-day follow-up, 12% (n = 5) in the control group had died, and 2%  
(n = 1) from the experimental group had died. There was a significant difference 
in the mortality rate with the control group having more deaths than the 
experimental group (t = 1.99, df = 90, p = .04). These deaths were attributed to 
complications of heart failure. Table 11 displays the number of deaths by group 
assignment. 
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Table 11 
Total Number and Percent of Deaths per Group Assignment  
 Sample 
 
     Deaths 
Number/ Percent by group 
Experimental Group 
(n = 50) 
     
        1        (2%) 
Control Group 
(n = 42) 
Total (N = 92) 
 
5 (10%) 
6 (5%) 
 
To summarize, hypotheses one and two were not supported, but an 
ancillary finding showed a significant difference in the mortality rate. Additionally, 
BNP levels and QOL scores were significantly correlated but with a weak 
magnitude for both groups at baseline.  A more in-depth discussion of findings, 
limitations, implications for nursing, and recommendations for future study will be 
described in chapter five.  
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Chapter 5 
Discussion, Conclusions, and Recommendations 
Introduction 
 This chapter presents a broad discussion of the findings, conclusions, 
implications, limitations, and recommendations for future research. In the 
discussion section, hypotheses one and two are discussed in detail. Several 
plausible explanations are offered for the findings of each hypothesis. The factors 
that limit the generalizability of the study are discussed. Finally recommendations 
for future research are included. 
Discussion 
Hypothesis 1 
  Previous research on QOL and its relation to BNP levels in HF has been 
widely studied. However, little has been known about whether a physician’s 
knowledge or lack of knowledge of BNP levels affects QOL scores and hospital 
LOS at 90 days. It was hypothesized that if physicians were aware of BNP levels, 
then appropriate treatment would circumvent the development and progression 
of HF. Additionally, timely treatment would help alleviate and ease the symptoms 
of HF and might improve the patient’s quality of life. In the current study, the 
physician’s knowledge of BNP levels at the time of the clinic visit did not have 
any significant effect on the QOL scores for either the experimental or the control 
group at 90 days. Despite the fact that no significant association was observed 
between the experimental and control group at 90 days, the data indicated a 
decrease in the mean QOL scores at 90 days (37.46 ± 28.67) as compared to 
 99
the mean QOL scores at baseline (46.87 ± 29.63) for both groups. Because the 
QOL scale is reversed, this indicated that there was a positive change in QOL 
scores during the 90-day interval. 
 There are several plausible explanations for this outcome. First, the data 
showed a QOL mean of 45.9 ± 29.8 and 48.6 ± 29.3 for the experimental and 
control groups, respectively. Although, these mean QOL scores at baseline 
demonstrated an impaired QOL (based on the range of 0-105), they may have 
had little room for improvement.  The patients’ QOL might already have been 
quite positive. It is possible that these HF patients may have adapted to their 
chronic disease and adjusted their perception of their QOL. This lack of room for 
improvement reflects a ceiling effect.  
 Second, another possible explanation for failing to detect a significant 
difference between the experimental and control groups on QOL scores at 90 
days could have been that the same physician was treating both groups. The 
patients were already well managed, as evidenced by the BNP level of 101 pg 
per ml as mode. The clinician continued to provide optimum care to each group, 
and knowing current BNP values at the clinic visit may not have altered the 
clinician’s overall treatment plan for either group.  
  Third, it is possible that if the participants were newly diagnosed HF 
patients at baseline, the finding might have been different since new patients 
might not have adapted to their functional limitations and QOL. Perhaps at this 
point, quality of life is a not a stable construct in newly diagnosed HF patients. 
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Fourth, sample size may not have been large enough to detect a significant 
difference in QOL scores between the two groups.  
 Although hypothesis one was not supported, the lack of association 
between physician knowledge of BNP levels is an unusual finding, since previous 
studies suggested that clinicians’ knowledge of BNP-guided treatment provided 
alleviation of symptoms and improvement of QOL (Troughton, 2000).   
Hypothesis 2 
The data revealed no significant difference on the hospital LOS when 
comparing groups. In this study, the experimental group had a higher frequency 
of admission when compared to the control group; however, this was not 
statistically significant. Perhaps the physician’s awareness of the BNP levels for 
those participants in the experimental group prompted closer monitoring; this 
could have accounted for the increased number of hospitalizations. However, it 
does not explain the non-significant difference in the length of stay across the 
two groups. Three possible reasons are proposed; an obvious one is that the 
sample size of those admitted was quite limited. A second possible explanation is 
that the event rate of hospitalization was too low, and the study was not powered 
for this outcome.  Expanding the interval beyond 90 days might have allowed for 
more events to occur. Another possible explanation could be that the admitted 
HF patients were treated by different attending physicians with differing 
modalities of treatment.   
  The results of the second hypothesis was an unexpected finding since it 
has been suggested by Cheng et al. (2001) and Mueller et al. (2004) that 
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physician knowledge of BNP levels predicts shorter hospital LOS. Additionally, 
findings from a previous study concluded that patients who did not receive BNP-
guided treatment experienced more cardiovascular event hospitalizations and 
deaths (78%) than those receiving BNP-guided treatment (22%) (Troughton et 
al., 2000). BNP levels should not be interpreted in isolation, but as part of the 
whole clinical assessment of the patient.  
Ancillary Finding 
Additionally, the study revealed an ancillary finding, demonstrating that 
there was a statistically significant association between BNP at baseline and the 
physical subscale scores at baseline (r = .24, p = 0.01). This corroborated the 
idea that increased BNP levels indicated more severe HF symptoms as reflected 
in the QOL scores. Regardless of whether patients were randomized to the 
experimental or control groups, the data reflected that as BNP level increased, 
patients experienced more impaired quality of life and physical health. These 
findings were consistent with previous research concerning elevated BNP level 
and its association with bad prognosis and poor quality of life (Morrison et al. 
2002; Ninuma et al., 1998; Wieczorek et al., 2002; Lubarsky & Mandell, 2004; 
Hirata et al., 2001; Teboul et al., 2004; Sagnella, 1998; Vanderheyden et al., 
2004; Heidenreich et al., 2004; Mair et al., 1999; Valle et al., 2005). Findings of 
this study are similar to those of Mueller et al. (2004), Steg et al. (2005), and 
Maisel et al. (2002), who concluded that clinician’s knowledge of BNP levels as 
an additive diagnostic tool along with other clinical information is useful in 
assessing QOL. According to Heidenrich et al. (2004), Maisel et al. (2001), and 
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MacMahon et al. (2002), timely detection of BNP levels may lead to early 
diagnosis and treatment of CHF, thereby decreasing readmissions and improving 
patients’ quality of life. The results of this study extend these same findings to 
this clinic sample: increased BNP level directly correlated with QOL scores; an 
increased QOL score indicated more functional impairment. 
Another incidental finding was that the mean of NYHA II HF patients for 
this sample was higher (460 pg per ml) than reported by Maisel et al. (2001)  
(332 pg per ml). These results provided evidence that the participants in the 
NYHA II classification were sicker than those in the same NYHA II classification 
reported by Maisel et al. (2001). The mean for the NYHA III patients of this study 
was 569 pg/ml, similar to the mean of 590 pg per ml for NYHA III as reported by 
Maisel et al. (2001). Although the NYHA classification was made within 6 months 
of assessments, the discrepancy between the mean BNP of this sample when 
compared to the mean of BNP sample reported by Maisel et al. (2001) highlights 
the subjective validity of the classification. So even though the t-test showed no 
statistical difference at baseline between the two groups in the current study, 
there may have been a subjective difference in the clinical picture that affected 
the treatment by the physician, and therefore, the results. 
Additionally, data from this study showed a higher number of deaths in the 
control group as compared to the experimental group at 90 days (t = 1.99,  
df = 90, p = .04).  A possible explanation is the physician’s lack of awareness of 
BNP values; this may have distorted the assessment of the HF patient. 
Troughton et al. (2000) concluded that death rates and hospital admissions were 
 103
fewer in the BNP-guided group than in the clinical group (19 vs. 54, p = .02). Ishii 
et al. (2003) concluded that BNP levels were strong predictors of cardiac events 
and were associated with mortality rates. Therefore, further study is warranted to 
determine whether physicians’ lack of knowledge of BNP levels is related to 
increased heart failure mortality. Consequently, the use of BNP rapid assay and 
its modest cost ($26/ test), is crucial in comparison to heart failure’s enormous 
economic healthcare burden to society. Mueller et al. (2006) concluded that the 
cost effectiveness of BNP-guided testing in heart failure patients showed that 
total treatment cost of $7,930 for the BNP-guided group was significantly reduced 
from the $10,503 incurred by the control group (p<0.004).  
Limitations 
 Several limitations of this study warrant caution in interpreting the results. 
One major limitation is that the PI did not collect data on medications used for 
this cohort or track any change in medications from baseline to 90 days. A 
retrospective preliminary pilot study conducted at the same HF clinic indicated 
that these patients were receiving the optimum pharmacological treatment for 
HF. It was the researchers’ assumption that knowledge of BNP levels would 
somehow prompt the physician to improve their care. Perhaps the assumption 
that physician knowledge of BNP levels would have affected the physicians’ 
decision on the treatment rendered to the patient was incorrect. In retrospect, 
there were several variables that should have been controlled and analyzed. One 
such variable was the presence of cardiac devices like the biventricular 
pacemakers. As noted earlier, medication history was not obtained for all patients 
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at baseline or 90 days. These patients were likely receiving optimum medications 
for heart failure; however, changes in the medications were not tracked at the 90-
day interval. Such changes could have influenced any hospital admissions, LOS, 
and QOL. Another variable that could have been monitored was presence of 
comorbidities in these HF patients. These comorbidities, such as arthritis or 
emphysema, could have significantly impacted QOL.  
 Another limitation to the study was its setting. The study sample was 
recruited from one clinic in the Southeastern United States, limiting 
generalization of findings to other clinics and geographical areas. This was a 
unique clinic population consisting largely of elderly, African-American men who 
were relatively unwell. This limited heterogeneity amongst subjects. This sample 
may be similar to those who live in the northeastern region of Florida yet different 
from those who live in the southeastern region of Florida. Additionally, the study 
might have benefited from a larger sample size in order to better address attrition 
and be powered for a low base rate of hospitalizations. Given the low base rate 
for hospitalizations, a larger sample size might have permitted detection of a 
statistically significant difference between groups in the number of hospital 
admissions and LOS. Furthermore, there is a likelihood that participants of the 
study may have been enrolled in other heart failure studies in the past and may 
have been exposed to the same MLWHF questionnaire. Also, there is a 
possibility of excessive systematic error in the MLWHF questionnaire and a 
possibility of random error occurring in the BNP rapid assay machine. Lastly, 
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there exists the possibility of investigator bias since the PI was not blinded to 
group assignment.  
Implications for Nursing 
The implications drawn from this experimental study are presented in this 
section. As evidenced by the results, increased BNP levels are negatively 
associated with QOL in patients with heart failure. Based on this information, 
clinical nurses need to understand that BNP levels may be directly related to 
volume overload. Increased volume overload begets increased symptoms and 
increased functional limitations. Understanding the relationship of BNP levels in 
relation to these symptoms may help delay the progression of the disease, 
alleviate deterioration of functional status, and improve QOL. Thus, nurses need 
to keenly observe signs and symptoms of heart failure exacerbation; they need to 
know that BNP values are an additive diagnostic tool to be used in the context of 
all other available clinical information.  
Furthermore, knowledge of BNP levels empowers patients to make 
informed consumer decisions regarding their health conditions, such as 
importance of daily weights, compliance with medications, exercise, and proper 
diet. Physical indicators of heart failure are not as obvious as indicators of other 
disorders. For example, although HF patients can do daily weights, no objective 
at-home blood tests are currently available to assess volume status, but patients 
with diabetes have immediate access to point-of-care tests for blood glucose. 
Awareness of BNP level and its relationship to the pathophysiology of the 
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disease process would allow the patient to have better control and management 
of this chronic and debilitating condition.  
Recommendations for Future Study 
Based upon the results of this study as well as the review of literature, the 
following recommendations are made for future research. It is recommended that 
[a] this study be replicated using a larger sample size in order to detect any effect 
of knowledge of BNP levels to QOL and to detect low event rate such as 
hospitalizations; [b] the follow-up period be extended for more than 90 days to 
allow for the occurrence of more cardiovascular events; [c] correlations be 
retested between BNP and current NYHA classification to validate the use of 
BNP as a clinical marker, [d] other physiologic variables that heart failure patients 
experience (such as sleep disorders, implantation of cardiac devices, and effects 
of life-sustaining medications on patients’ QOL) be examined, [e] adding a 
psychological component such as a depression questionnaire may provide a 
more holistic view of how heart failure patients experience their quality of life; and 
[f] conducting a structural equation modeling procedure would provide a more 
comprehensive statistical analysis when attempting to evaluate the physical, 
psychological, and emotional dimensions when assessing the quality of life of 
heart failure patients. 
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Summary 
Managing congestive heart failure continues to present a challenge for 
nurses and other clinicians. The impact of heart failure on patients as well as its 
economic burden to society is undeniable. Despite a high level of public 
awareness of this disease, a majority of the population is unaware of their risks of 
developing heart failure. Nurses can educate heart failure patients, so they may 
empower themselves in circumventing the development of this clinical syndrome. 
Even though the hypotheses of this study were not supported, incidental 
findings warrant further research. The limitations, as previously discussed, 
should be addressed so that future studies in the same area have more power. 
The inclusion of additional variables would further enhance the study. Quality of 
life remains a key area of heart failure research and a focal point in the treatment 
and management of heart failure. 
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Appendices 
Appendix A 
Demographic Information Form 
 
1. Data Collection Date_____________ 
2. Subject code_____________ 
3. Date of clinic visit ________ 
4. Age (circle one): 
              [1] age 21 to 40 
              [2] age 41 to 60 
              [3]age 61 to 80 
              [4] age 90 and older 
5.  Ethnic Background (circle one):                          
              [1] Asian 
[2] African-American 
[3] Caucasian 
[4] Hispanic  
[5] Native American 
[6] other _____________________ 
6. Education (highest level achieved):  
   [1] Less than high School 
   [2] High school Diploma 
   [3] Some college 
   [4] 4 year Degree 
   [5] Masters Degree 
   [6] Doctoral Degree  
7. Occupation (circle one):  
             [1] Management 
             [2] Business, Finance and Administration 
             [3] Natural and Applied Sciences and related occupations 
             [4] Health Occupations 
             [5] Social Science Education, Government Service & Religion 
             [6] Art, Culture, Recreation and Sport 
             [7] Sales and Service 
             [8] Occupations unique to Primary Industry 
             [9] Occupations unique to Processing, Manufacturing and Utilities 
8.  Marital Status: 
  [1] Single 
  [2] Married 
  [3] Divorced 
            [4] Widow/ Widower 
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9.  Insurance:  
  [1] Yes 
  [2] No  
  10. Insurance Payers: 
              [1] Private Insurance 
              [2] Medicare 
              [3] Medicaid 
              [4] Tricare Military 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix B 
 
Subject Code_______                                                                              
Date_________
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Appendix C 
 
Medical Information Form 
 
Data Collection Date_____________                     Subject 
code___________________ 
     
      1. Hospital Admission   
          [A] Yes 
          [B] No 
      2. If admitted:                                                                                       
          [A] Date of admission_____________                                                           
          [B] Hospital_____________________ 
          [C] Diagnosis___________________                                                            
          [C] Date of discharge_____________ 
      3. NYHA Classification 
          [A] NYHA I 
          [B] NYHA II 
          [C] NYHA III 
          [D] NYHA IV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix D 
Letter of Support from Medical Director 
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Appendix E 
Informed Consent Form 
 
                IRB# UFJ-2005-50/ USF 103600 
 
Informed Consent to Participate in Research 
 
The University of Florida 
Health Science Center 
Jacksonville, Florida 32209 
 
You are being asked to participate in a research study.  This form provides you with 
information about the study. The Principal Investigator (Irma B. Ancheta) will 
describe this study to you and answer all of your questions. Before you decide 
whether or not to take part, read the information below and ask questions about 
anything you do not understand.  
1.  Name of the Participant  
2.  Title of Research Study 
 
“The relationship between of b-type natriuretic peptide (BNP) levels and hospital 
length of stay and quality of life in congestive heart failure patients” 
 
3.  Principal Investigator(s), Address and Telephone Number(s)  
 
Irma B. Ancheta RN, MSN 
4120 Shoal Creek Lane East 
Jacksonville, Fl. 32225 
(904) 645-3862 
(904) 629-7923 
 
4.  Source of Funding or Other Material Support 
 
None 
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IRB# UFJ-2005-50/ USF 103600  
5. What is the purpose of this research study? 
The purpose of the study is to find out if physician’s knowledge of your blood levels 
of the result of a particular blood test will affect the management of your illness, 
hospital length of stay and quality of life. This blood test measures the level of BNP, 
or B-type natriuretic peptide present in your blood. BNP is a substance secreted 
from lower chambers of the heart, in response to changes in pressure that occur 
when heart failure develops or worsens. 
 
You are being asked if you are interested in taking part of this study because you 
have been diagnosed with congestive heart failure. Your doctors and researchers 
involved with heart failure patients around the country would like to learn more 
about this condition. Approximately 160 patients will participate at our site for this 
study. 
 
6.  What will be done if you take part in this research study? 
 
• You will be asked to respond to two questionnaires that would take about 15 
minutes of your time. The questionnaire will ask you how living with congestive 
heart failure has affected your life. You will be asked to respond to the same 
questionnaire in 90 days in the privacy of this clinic office. 
• Approximately one cc (about ½ teaspoon) of your blood will be drawn from a 
vein to test for BNP levels in the clinic. 
• You will be randomly (like a flip of a coin) put in a group who will have the BNP 
blood test disclosed to the physician or in the group whose BNP levels will not be 
disclosed to the physician.  
• You will allow us to follow up and record any heart failure hospitalization in the 
next 90 days. 
• Information from your clinic visit and medical record will be collected such as 
age, gender, ethnicity, education, marital status, insurance payers, the severity of 
your congestive heart failure, the date of any potential hospital admission, what the 
diagnosis was and the date of hospital discharge. 
• You will be contacted by phone or during your normal clinic visits at monthly 
intervals for the next three months to find out how you are doing.  During these 
follow-ups we will be inquiring about whether or not you have been in the hospital.   
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        IRB# UFJ-2005-50/ USF 103600                         
 
 
7. What are the possible discomforts and risks? 
 
Blood Sampling 
The risks may include discomfort at the puncture site; possible bruising and 
swelling     around the site; and uncommonly, faintness; and rarely, an infection. 
Potential risks may involve violation of confidentiality, embarrassment or discomfort 
that might arise if the data regarding your diagnosis, hospital length of stay and 
quality of life survey is unnecessary exposed. Your answers are confidential and 
we will take all necessary precautions to ensure your confidentiality.   
 
                                                                                             
8a. What are the possible benefits to you? 
 
There are no direct benefits to you for taking part in this study, but the information 
gained from your participation may help other patients. 
 
8b. What are the possible benefits to others?  
 
As an outcome of this study, the possible benefits to others might include improving 
quality of life and reducing hospital length of stay for future congestive heart failure 
patients. 
 
9.  If you choose to take part in this research study, will it cost you anything? 
 
The study will not cost you anything. 
 
10.  Will you receive compensation for taking part in this research study? 
 
You will not receive compensation for taking part in this study. 
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        IRB# UFJ-2005-50/ USF 103600                        
 
11. What if you are injured because of the study? 
 
If you experience an injury that is directly caused by this study, only professional  
care that you receive at the University of Florida Health Science Center will be 
provided without charge.  You may call the Shands Cardiovascular Center at (904) 
244-4198 or your principal investigator (Irma B. Ancheta) at (904) 645-3862. 
However, hospital expenses will have to be paid by you or your insurance provider.  
No other compensation is offered.   
 
If you are harmed while taking part in the study: The state of Florida enjoys what is 
called "sovereign immunity."  This means that you usually cannot sue the state of 
Florida.  However, the state has waived sovereign immunity (agreed to be sued) in 
certain situations.  One of those situations is if a state employee, such as your 
study doctor or other USF employee is negligent in doing his or her job in a way 
that harms you during the study.  The money that you might recover from the state 
of Florida is limited in amount. 
You can also call the University of South Florida Self Insurance Programs (SIP) at  
1-813-974-8008 if you think: 
• You were harmed because you took part in this study. 
• Someone from the study did something wrong that caused you harm, or 
didn’t do something they should have done. 
• Ask the SIP to look into what happened.                                                                            
12.  What other options or treatments are available if you do not want to be in 
this study? 
 
If you do not want to take part in this study, tell the principal Investigator (Irma B. 
Ancheta) you do not want to participate in the study. 
 
13a. Can you withdraw from this research study? 
 
You are free to withdraw your consent and to stop participating in this research study 
at any time.  If you do withdraw your consent, there will be no penalty and you will 
not lose any benefits you are entitled to. 
 
If you decide to withdraw your consent to participate in this research study for any 
reason, you should contact: Irma Ancheta at  
(904) 645-3862.  If you have any questions regarding your rights as a research 
subject, you may phone the University of Florida Institutional Review Board (IRB) 
office at (904) 244-3136 and the University of South Florida Institutional  Review 
Board (IRB) office at (813) 974-5638.   
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13b. If you withdraw, can information about you still be used and/or collected?  
 
If you withdraw, we would like to retain the surveys and questionnaires that you 
have responded during the initial interview. We would like your permission to 
continue to collect information from your physician or your medical records.  
Please initial:  
Yes_____  If I choose to withdraw from the study you may continue to use my 
personal data that has been collected. 
No_______If I choose to withdraw from the study, you may not continue to use my 
personal data that has been collected. 
 
 
13c. Can the Principal Investigator withdraw you from this research study? 
 
You may be withdrawn from the study for the following reasons: 
 
[A] If knowledge of any unexpected or unexplained side effects that affect your 
safety becomes known; 
 [B] If on receiving new information about the treatment, your PI (Irma B. Ancheta) 
might consider it to be in your best interests to withdraw you from the study without 
your consent if they judge that it would be better for your health. An example of this 
is when the study shows that an increased number of congestive heart failure 
patients die as a result of failure to report BNP levels. 
                                                                                        
                                                                                          
14.  How will your privacy and the confidentiality of your research records be 
protected? 
 
Authorized persons from the University of Florida and the University of South 
Florida, have the legal right to review your research records and will protect the 
confidentiality of those records to the extent permitted by law.  Otherwise, your 
research records will not be released without your consent unless required by law or 
a court order. If the results of this research are published or presented at scientific 
meetings, your identity will not be disclosed. 
 
 
15. If you agree to participate in this research study, what protected health 
information about you may be collected, used and disclosed to others?  
 
Your diagnosis, number of days in hospital and results of your BNP levels may be 
collected, used and disclosed to others. 
 
        IRB# UFJ-2005-50/ USF 103600                        
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16. For what study-related purposes will your protected health information be 
collected, used and disclosed to others? 
 
Your protected health information may be collected, used and disclosed to others to 
determine eligibility for the study. Other protected health information collected, used 
and disclosed to others would include study information such as your diagnosis and 
number of days in hospital. 
 
17. Who will be authorized to collect, use and disclose to others your 
protected health information? 
 
Your protected health information may be collected, used, and disclosed to others 
by 
the study principal investigator (Irma B. Ancheta, RN) and other employees at the 
University of South Florida  
- other professionals at the University of Florida or Shands Hospital that provide 
study-related treatment or procedures 
- the University of Florida and University of South Florida Institutional Review 
Boards. 
 
18. Once collected or used, who may your protected health information be 
disclosed to? 
 
Your protected health information may be given to: 
The study investigator, co-investigators, supervisors and the University of Florida 
and University of South Florida Institutional Review Boards (IRB). 
                                                                          
19. If you agree to participate in this research, how long will your protected 
health information be collected, used and disclosed?  
 
Your information will be maintained in a password protected database for 5 years. 
 
20.  Why are you being asked to authorize the collection, use and disclosure 
to others of your protected health information? 
 
Under a new Federal Law, researchers cannot collect, use or disclose any of your 
protected health information for research unless you allow them to by signing this 
consent and authorization form. 
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21. Are you required to sign this consent and authorization and allow the 
researchers to collect, use and disclose (give) to others of your protected 
health information?  
 
No, and your refusal to sign will not affect your treatment, enrollment, or eligibility for 
any benefits outside this research study. However, you cannot participate in this 
research unless you allow the collection, use and disclosure of your protected health 
information by signing this consent/authorization. 
 
22. Can you review or copy your protected health information collected, used 
or disclosed under this authorization? 
 
You have the right to review and copy your protected health information. However, 
you will not be allowed to do so until after the study is finished. 
 
23. Is there a risk that your protected health information could be given to 
others beyond your authorization? 
 
Yes. There is a risk that information received by authorized persons could be 
given to others beyond your authorization and not covered by the law. To 
ensure confidentiality all data will be recorded in a secure, password-protected 
data file, the PI (Irma B. Ancheta) and the Institutional Review Boards (IRB) of 
the University of Florida and University of South Florida will have access to the 
database.  
 
24. Can you revoke (cancel) your authorization for collection, use and 
disclosure of your protected health information? 
 
Yes. You can revoke your authorization at any time before, during or after your 
participation in the research. If you revoke, no new information will be collected 
about you. However, information that was already collected may be still be used and 
disclosed to others if the researchers have relied on it to complete and protect the 
validity of the research. You can revoke this authorization by giving a written request 
with your signature on it to the Principal Investigator. 
                                                                    
 
25. How will the researcher(s) benefit from your being in this study? 
 
The PI (Irma B. Ancheta) will learn more about how to care for congestive heart 
failure patients and further the science.                                                     
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26. Signatures  
 
As a representative of this study, I, Irma B. Ancheta, have explained to the 
participant the purpose, the procedures, the possible benefits, and the risks of this 
research study; the alternatives to being in the study; and how privacy will be 
protected: 
 
 
_________________________________________           ___________ 
Signature of Person Obtaining Consent            Date 
 
 
You have been informed about this study’s purpose, procedures, possible benefits, 
and risks; the alternatives to being in the study; and how your privacy will be 
protected.  You will receive a copy of this form.  You have been given the 
opportunity to ask questions before you sign, and you have been told that you can 
ask other questions at any time.   
 
You voluntarily agree to participate in this study.  By signing this form, you are not 
waiving any of your legal rights. 
 
 
__________________________________________             __________ 
Signature of Person Consenting      Date 
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Appendix F 
 
Frequently Asks Questions 
 
1. What is the purpose of the study?  
The purpose of the study is to find out if this blood test can help improve your care 
and keep your heart failure symptoms under control.  
 
2. What does the study involve? 
The study will involve having to have a small amount of blood drawn, about 1 ml, 
from a vein to test your blood levels for heart failure. This will only be done once 
during your clinic visit. You will also be asked to answer a survey of 21 questions 
pertaining to the physical, psychological and emotional aspects of having to live 
with congestive heart failure. This survey will be done once during the clinic visit 
and again in 90 days in the clinic or via telephone. You will also be asked to report 
to the Principal Investigator (PI) any hospital admissions within the next 90 days. 
 
3. What happens if I do not want to participate in this study? 
The study is entirely voluntary. Non-participation will not in any way hinder your 
standard of care. 
 
4. Can I refrain from the study anytime?  
You may elect to refrain from the study at any time. You may withdraw from the 
study at any time by telephoning or writing the Principal Investigator. 
 
5. Will it cost me to participate in the study? 
You will not have any additional costs because of your involvement in this study. 
 
6. How long is the study? 
The study will run for 90 days from time of clinic visit. 
 
7. Will I have the chance to know the results of the study? 
Once study is completed the results of the study will be available to you if you so 
desire. 
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